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Abstract 
 Diet has an important role in the maintenance of oral health, but the relationship 
between diet and clinical outcomes following sanative therapy (ST) has not been 
investigated. Due to their antioxidant and anti-inflammatory properties, we hypothesized 
that periodontal patients with higher intakes of vitamin C, vitamin D, eicosapentaenoic 
acid (EPA) or docosahexaenoic acid (DHA) would have greater reductions in probing 
depth (PD) after ST. Patients completed the Block food frequency questionnaire, a 
supplement use questionnaire and had their serum 25-hydroxyvitamin D measured. There 
were no significant associations between intakes of vitamin C, vitamin D, EPA, DHA and 
PD. There were, however, negative associations between intakes of linoleic acid, α-
linolenic acid or total vegetable intake and PD, as well as a positive association between 
the total omega-6/omega-3 ratio and PD (p < 0.05). Therefore, dietary intakes of essential 
fatty acids and vegetables may be important modulators of periodontal outcomes 
following ST.    
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1.1 Periodontal Disease 
Periodontal disease is a condition characterized by inflammation of the tissues 
that surround and support the teeth. It is caused by bacteria on the surface of the teeth and 
below the gum line, as well as an over active immune response to that bacteria. In 
periodontal disease, inflammation results in loss of connective tissue supporting the teeth 
and loss of alveolar bone from the jaw. Unlike gingivitis, which is a reversible condition, 
periodontitis is chronic and often non-reversible. If left untreated, patients with 
periodontal disease will lose their teeth.  
 According to the 2007-2009 Canadian Health Measures Survey, 16% of Canadian 
adults (20 – 79 years of age) have moderate periodontal disease while 4% of Canadian 
adults of severe periodontal disease [1]. The prevalence is also higher in specific 
populations. For example, 24% of older Canadian adults (60 – 79 years of age) have signs 
of moderate periodontal disease and 22% of current smokers have signs of moderate 
periodontal disease. 
 
1.1.1 Anatomy and Definitions 
1.1.1.1 Anatomy of the Periodontium 
The periodontium consists of both hard and soft tissues. The hard tissues of the 
periodontium include the alveolar bone and cementum while the soft tissues include the 
periodontal ligament and gingivae [2] (Figure 1.1). Alveolar bone is a specialized type of 
bone that sits over the jaw and forms sockets in which the teeth sit. Alveolar bone is 
composed of an outer periostium, an underlying layer of compact bone, and the inside is 
composed of cancellous bone. Alveolar bone is laid down by osteoblasts, maintained by 
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osteocytes, and broken down by osteoclasts to allow for remodeling.   The cementum is a 
hard tissue covering of the root of a tooth. It is primarily composed of calcium 
hydroxyapatite crystals embedded in fibrous tissues. The cementum is formed by 
cementoblasts and maintained by cementocytes. The periodontal ligament forms a 
connective tissue attachment between the cementum and the alveolar bone. It consists of 
directional collagen bundles running between the alveolar bone and cementum and 
between adjacent teeth and gingivae. Periodontal ligament attaches to bone and 
cementum through specialized fibres called Sharpey’s fibres. The periodontal ligament 
acts as a shock absorber during normal activities such as chewing. It is also highly 
vascularized and rich in sensory nerve fibres. The periodontal ligament and fibrous 
connective tissues are formed by fibroblasts and by the epithelial cells of the gingivae. 
The gingivae (or gums) are a special connective tissue covering that attaches to teeth at 
their necks. It is composed of a surface keratinized epithelium, which forms part of the 
oral mucosa. There are three types of gingivae; attached gingivae that lays on top of 
alveolar bone, marginal gingivae that forms the gingival margin (does not sit on top of 
bone) and junctional tissue that forms the anatomical junction between the teeth and the 
oral epithelium. In healthy individuals, the junctional tissue attaches at the cemento-
enamel junction. The top of the gingivae is known as the gingival margin and the pit-like 
depression between the gingival margin and the junctional epithelium forms the gingival 
crevice.  
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Figure 1.1 Anatomy of the periodontium.  
 
1.1.1.2 Clinical Measures 
Periodontal status is assessed through a number of clinical markers. Probing depth 
(PD) is a measure of the distance from the gingival margin to the bottom of the gingival 
crevice. A probing depth of 3 millimeters (mm) or less is normal, while a probing depth 
of 4 mm or more indicates periodontal disease. PD is routinely used to evaluate disease 
severity, disease progression and response to treatment [3].  Another common measure is 
gingival recession (GR), which is a measure of the exposure of the root surface. GR is 
measured as the distance between the gingival margin and the cemento-enamel junction. 
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Clinical attachment loss (CAL) is the distance between the cemento-enamel junction and 
the bottom of the gingival crevice. When the gingival margin is below the cemento-
enamel junction, CAL is the sum of PD and GR. Measurements of PD, CAL and GR are 
demonstrated in Figure 1.2. CAL is accepted as the gold standard for periodontitis, 
however, it is considered a better measure of past periodontal disease activity, whereas 
PD is a better measure of present periodontal disease activity [4]. This is because when 
periodontitis is treated, inflammation resolves and PD is returned to normal but GR may 
still be present. For these reasons, CAL and PD are both used in epidemiology and 
clinical trials, however, since CAL is cumbersome and time consuming to measure, PD 
alone is usually used to measure disease activity in a clinical setting. Other common 
measures include bleeding on probing and plaque score. Bleeding on probing (BOP) is 
the number of sites that bleed when probed and is a measure of acute inflammation and 
oral hygiene care. Plaque score is the number of teeth with visible plaque and is a useful 
measure because it reflects a patient’s hygiene practices. PD, CAL and BOP are 
measured at six sites around each tooth; three sites on the front surface (buccal, mesial 
buccal, and distal buccal) and three sites on the back surface (lingual, mesial lingual, 
distal lingual).  
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Figure 1.2 Measurement of recession, probing depth and clinical attachment loss.   
 
1.1.1.3 Definition of Periodontal Disease 
 The current classification system for periodontal disease was established in 1999 
by the American Academy of Periodontology [5]. They define chronic periodontitis as 
‘‘an infectious disease resulting in inﬂammation within the supporting structures of teeth, 
progressive attachment and bone loss. It is characterized by pocket formation and/or 
gingival recession. It is recognized as the most frequently occurring form of periodontitis. 
Its onset may be at any age but is most commonly detected in adults. The prevalence and 
severity of the disease increases with age. It may affect a variable number of teeth and 
has variable rates of progression.’’ Chronic periodontitis can be classified as either 
localized or generalized. Localized periodontitis is when ≤ 30% of sites are affected and 
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generalized periodontitis is when > 30% of sites are affected. Periodontitis can be further 
classified based on severity. Moderate periodontitis is defined as having ≥ 2 
interproximal sites (mesial or distal) with CAL ≥ 4 mm (not on same tooth) or ≥ 2 
interproximal sites with PD ≥ 5 mm (not on same tooth). Severe periodontitis is defined 
as having ≥ 2 interproximal sites with CAL ≥ 6 mm (not on same tooth) and ≥ 1 
interproximal site with PD ≥ 5 mm.      
 
1.1.2 Pathogenesis of Periodontal Disease 
The initiation of periodontal disease begins with chronic bacterial exposure. 
Although pathogenic organisms are a prerequisite for periodontitis, it has been estimated 
that bacterial exposure only accounts for approximately 20% of disease expression [6]. 
Therefore, periodontal disease is largely driven by host factors, namely the host immune 
response. In response to bacteria and bacterial biofilms, immune cells such as neutrophils, 
macrophages, B cells and T cells are recruited into the periodontium [7]. This results in 
the release of pro-inflammatory cytokines, matrix metalloproteinases (MMPs), reactive 
oxygen species (ROS), and mediators for osteoclastic bone resorption.  
Periodontitis ultimately results in both soft tissue (periodontal ligament and 
gingivae) and hard tissue (alveolar bone) destruction. Most of the soft tissue destruction 
is mediated by MMPs. MMPs are released by a variety of host cells such as 
polymorphonuclear leukocytes, macrophages, fibroblasts, bone, epithelial, and 
endothelial cells and they catalyze the breakdown of the cell membrane and extracellular 
matrix proteins such as collagen, gelatin, proteoglycans, fibronectin, laminin, and elastin 
[8]. Periodontal disease is characterized by an imbalance in MMP activity. For example, 
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there is increased secretion of MMP-8 (neutrophil-derived collagenase) and MMP-9 
(neutrophil-derived gelatinase) by polymorphonuclear cells (PMNs), which effectively 
degrade the type 1 collagen found in periodontal ligament and gingivae [9]. Furthermore, 
transcription of MMP genes is up regulated by cytokines known to be important in 
periodontal disease progression, including interleukin (IL)-1β and tumor necrosis factor 
alpha (TNF-α) [10]. Hard tissue destruction is largely mediated by over activity of 
osteoclasts. Osteoclast differentiation and activity is directly up regulated by the immune 
response through mediators such as IL-1ß, TNF-α, IL-6 [11, 12]. In addition, reactive 
oxygen species (ROS) play an important role in the pathogenesis of periodontal disease. 
ROS are a diverse group of oxygen containing molecules with unpaired electrons, which 
makes them extremely reactive and capable of oxidizing and damaging biological 
molecules. Immune cells, especially neutrophils generate ROS in periodontal tissue as 
part of the normal response to bacterial pathogens [13]. ROS has been shown to cause 
lysis of gingival epithelial cells [14], activate osteoclasts [15], cause de-polymerization 
and residue modification of extracellular matrix proteins [16], modify type 1 collagen 
making it more susceptible to proteolysis [17] and up regulate MMP expression [18]. A 
simplified schematic of periodontal tissue destruction is depicted in Figure 1.3.  
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Figure 1.3 Pathogenesis of periodontal disease.  
 
1.1.3 Risk Factors for Periodontal Disease 
The prevalence and severity of periodontal disease has been associated with both 
genetic and environmental risk factors [19].  
 
1.1.3.1 Non-Modifiable Risk Factors (genetics, sex, age) 
Familial aggregation studies have demonstrated a significant genetic component 
to periodontal disease and that genetics may account for up to 50% of disease expression 
in adults [20]. The identification of specific genetic risk factors for periodontal disease is 
one of the current challenges in periodontal research. Vijayalakshmi [21] has provided an 
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excellent summary of genetic polymorphisms identified to date. Examples include 
polymorphisms in genes for cytokines (IL-1, TNFα, IL-10), receptors (Fc gamma 
receptor, formyl peptide receptor 1), metabolism (vitamin D receptor, calcitonin 
receptor), antigen recognition (human leukocyte antigens) and innate immunity receptors 
(toll-like receptor 2 and 4, CD14, caspase recruitment domain-containing protein 15). 
These associations, however, are based on a limited number of studies and therefore the 
clinical implications of these findings are not yet known.  
Age and sex have also been identified as risk factors for periodontal disease. 
There is a greater prevalence of periodontal disease with age; however, this appears to be 
mediated by oral hygiene status rather than by age itself [22]. In this study, oral hygiene 
status was defined as either good or poor depending on the need for professional removal 
of plaque and calculus (hardened plaque). The prevalence of periodontitis has also been 
shown to be higher in males compared to females; however, it is thought that this 
phenomenon is largely attributable to behavioral differences [23]. The greater prevalence 
seen in men may be due to lower frequency of brushing and flossing [24], greater tobacco 
use [25] and less frequent use of oral health care services [26].  
 
1.1.3.2 Modifiable Risk Factors (oral hygiene, smoking, stress, obesity, systemic 
diseases) 
Numerous modifiable risk factors have been identified and include oral hygiene, 
smoking, stress, obesity, and the presence of systemic diseases. Systemic diseases will be 
reviewed in section 1.1.4.   
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Oral hygiene, especially plaque control, is an extremely important component of 
periodontal disease prevention and management [27]. This is true because the removal of 
plaque removes the etiological agent of periodontal disease. Interestingly though, a meta-
analysis has concluded that there is no evidence that personal oral hygiene care prevents 
or controls chronic periodontitis [28]. However, this finding may be due to the use of 
measures such as brushing frequency and technique to assess oral hygiene, which do not 
take oral hygiene efficacy (the actual success of plaque removal) into account [19]. 
Surrogate measures of oral hygiene care such as plaque score are significantly related to 
measures of early periodontitis [29].  
Smoking is undeniably a significant risk factor for periodontal disease. 
Epidemiological evidence from the National Health and Nutrition Examination Survey 
(NHANES) in the United States has suggested that approximately half of the 
periodontitis cases are attributed to smoking [30]. The mechanisms are not fully 
understood but smoking is associated with lower levels of anti-inflammatory and anti-
resorptive factors such as IL-10 and osteoprotegerin (OPG) and higher levels of pro-
inflammatory cytokines such as IL-6 and interferon gamma (INF-λ) in periodontal tissues 
[31]. It is also known that smokers have a lower proportion of blood vessels in 
periodontal tissue and therefore a reduced blood flow to the area [32]. When it comes to 
periodontal disease treatment, most clinical studies show that both surgical and non-
surgical periodontal therapies are less effective in smokers [33]. Fortunately, there are 
several studies that report benefits to periodontal health and treatment with smoking 
cessation [34] although being a former smoker is still associated with some risk of 
periodontal disease [30]. 
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Stress is currently considered a risk factor for periodontal disease [35]. The 
mechanisms have not been fully elucidated but the relationship is thought to arise through 
health-impairing behaviors (poor oral hygiene, smoking, alcohol consumption, and poor 
nutritional intake) and physiological factors such as higher glucocorticoid levels that may 
contribute to inflammation.  
It has been estimated that after dental plaque and smoking, obesity is the next 
biggest risk factor for periodontal disease [36]. Most of the evidence for this association 
is epidemiological. A body mass index (BMI) of 25-29.9 confers a relative risk for 
periodontitis of 3.4 while a BMI greater than 30 confers a relative risk of 8.6 [37]. BMI is 
also significantly correlated with the severity of attachment loss with greater attachment 
loss when insulin resistance is present [38]. Additionally, it has been shown that the 
distribution of fat is an important consideration as waist-to-hip ratio may be a better 
predictor of periodontal disease than BMI [39]. Furthermore, physical activity has been 
associated with a lower prevalence of periodontitis [40]. The underlying mechanism is 
not yet known but it is suspected to be due to inflammatory cytokines and adipokines 
derived by adipose tissue [19]. 
 
1.1.4 Periodontal Disease and Systemic Conditions 
Periodontal disease is associated with a number of other chronic diseases 
including diabetes, cardiovascular disease, osteoporosis, respiratory diseases and 
rheumatoid arthritis. Clinically, it is important for dental professionals to assess a 
patient’s overall health in order to identify those at greater risk for periodontitis. 
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Similarly, the presence of systemic conditions may also have important implications for 
designing treatment plans for patients with periodontitis.     
 
1.1.4.1 Diabetes  
A meta-analysis of 57 studies concluded that type 2 diabetes mellitus is a risk 
factor for periodontitis [41]. On average, patients with diabetes have 1 mm more clinical 
attachment loss compared to non-diabetics. The proposed mechanism is thought to be 
through high levels of advanced glycosylation end products in periodontal tissue [42]. 
These end products bind to immune cells and fibroblast resulting in a hypersensitive 
response to pathogens (increased cytokine expression and increased mediators of both 
hard and soft tissue destruction). Moreover, these end products inhibit collagen formation 
by fibroblasts and thereby impair wound healing.  
Because inflammation promotes insulin resistance and dysregulation of glycemia 
[43], it is plausible that periodontal treatment can improve glycemic control in diabetics. 
Two meta-analyses have concluded that periodontal therapy can reduce hemoglobin A1c 
(HbA1c) levels significantly by 0.40% [44, 45]. This has significant clinical implications 
as a 0.20% reduction in HbA1c has been associated with a 10% decrease in mortality in 
the general population [46].    
 
1.1.4.2 Cardiovascular Disease  
Cardiovascular diseases are one of the leading causes of death worldwide. 
Cardiovascular diseases describe a broad range of pathologies that include ischemic heart 
disease, ischemic stroke, and myocardial infarction.  Based on the results from several 
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meta-analyses, the Canadian Dental Association has concluded that there is a significant 
relationship between periodontitis and cardiovascular disease independent of other risk 
factors [47]. This association may be explained by the fact that many of the systemic 
markers in periodontal disease [C-reactive protein (CRP), IL-1β, IL-6, IL-8, TNF-α] are 
also associated with cardiovascular disease [48]. Furthermore, periodontal disease has 
been associated with endothelial dysfunction, another risk factor cardiovascular disease 
[49]. There is strong evidence that periodontal treatment reduces c-reactive protein levels 
and improves endothelial function while there is a moderate amount of evidence 
suggesting periodontal therapy reduces IL-6 and lipid levels [50, 51]. It is likely that 
these changes translate into a reduced risk for cardiovascular diseases but the magnitude 
of these effects has not yet been calculated.   
 
1.1.4.3 Osteoporosis 
Osteoporosis is a skeletal disorder characterized by low bone mass and 
microarchitecture deterioration, which predispose an individual to fragility fractures. 
Postmenopausal women with osteoporosis, especially, are at a significantly higher risk 
(odds ratio of 2.58) for periodontal disease [52]. We have also known for decades that 
there is an inverse relationship between bone mineral density and tooth loss [53-55]. The 
relationship between periodontitis and osteoporosis likely stems from the fact that they 
share many pathological features in common such as an increase in inflammation and an 
increase in bone resorption. In a recent study, it was suggested that the relation between 
these two diseases is at least partly mediated by low vitamin D, increased receptor 
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activator of nuclear factor kappa-B ligand (RANKL) and an increase in inflammatory 
cytokines [56]. 
 
1.1.4.4 Respiratory Diseases 
Periodontal disease has been associated with an increased risk for both 
nosocomial bacterial pneumonia (NBP) and chronic obstructive pulmonary disease 
(COPD) [57]. The incidence of NBP in people with periodontitis has been attributed to 
colonization of the respiratory tract by pathogens in dental plaque [58]. Fortunately, 
professional oral hygiene care has been shown to reduce the incidence of pneumonia in 
high-risk patients (e.g. elderly people in nursing homes) [59]. It is currently unknown if 
there is a direct cause and effect relationship between periodontal disease and COPD 
[60]. Nonetheless, since both NBP and COPD have high mortality rates, periodontal 
treatment and dental care provide a cost effective way to help prevent these life 
threatening diseases.  
 
1.1.4.5 Rheumatoid Arthritis  
Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disorder that 
can lead to severe disability and increased risk of mortality [61]. The relationship 
between periodontitis and RA has been recognized since the 1820s [62]. Similarly to 
other diseases, the link is likely due to the similarities in underlying inflammatory 
mechanisms. There is also speculation that periodontal pathogens might induce RA 
because they have been found in joints of patients with RA [63]. A clear cause and effect 
	   16	  
relationship, however, has not been established. One study has shown that anti TNF-α 
therapy is more effective in RA patients without periodontitis [64].  
It is evident that periodontal disease needs to be evaluated in the context of 
overall health. Clinicians and researchers need to be aware of the links between specific 
diseases and periodontitis in order to identify those at risk for periodontal destruction and 
to develop treatment plans. Importantly, periodontal therapy may involve the 
management of related conditions and conversely, the management of many chronic 
diseases may involve the treatment of periodontitis.    
 
1.1.5 Sanative Therapy for the Treatment of Periodontal Disease 
Sanative therapy (ST) is a conservative and cost-effective first line of treatment to 
manage periodontal infections. The goal of ST is to remove plaque and calculus from the 
root surfaces and to provide a root surface that is compatible with reattachment [65]. ST 
is performed using mechanical scaling instruments to remove bacteria that have invaded 
deep into the periodontal pocket below the gingival margin. ST is done by a process 
known as scaling and root planing.  Scaling is the “instrumentation of the crown and root 
surfaces of the teeth to remove plaque, calculus, and stains from these surfaces” and root 
planing is “a treatment procedure designed to remove cementum or surface dentin that is 
rough, impregnated with calculus, or contaminated with toxins or microorganisms” [66]. 
Scaling and root planing are performed with mechanical debridement instruments and 
sonic or ultrasonic scalers that use vibration accompanied by a stream of water to remove 
adherent deposits from teeth. The procedure is invasive and requires the use of local 
anesthesia. Once sub-gingival plaque and bacteria are under control, the immune 
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response can resolve. This means a reduction in inflammation, inflammatory cytokines, 
ROS, MMP activity and osteoclast activity. Once these destructive processes have 
subsided, healing and regeneration can take place. Successful ST results in a decrease in 
probing depths by reducing gingival swelling and allowing for new soft tissue formation 
to occur. There will be an increase in collagen fiber formation resulting in improved 
health of the periodontal ligament and junctional epithelium, ultimately leading to greater 
tooth attachment [67]. Although ST therapy can prevent further alveolar bone loss, unlike 
soft tissue, there is minimal regeneration of alveolar bone [68].   
 
1.1.6 Periodontal Healing: Regeneration and Repair 
 Periodontal healing is comprised of two distinct but simultaneously occurring 
processes, periodontal regeneration and periodontal repair. In an ideal situation, 
regeneration would outweigh repair, however, this is not usually the case.   
 
1.1.6.1 Periodontal Regeneration 
 Periodontal regeneration is defined as “restoration of lost periodontium” implying 
the restoration of architecture (alveolar bone, cementum, periodontal ligament and 
gingivae) and function [66]. Periodontal regeneration is a complex process involving 
many different cell types working in a coordinated sequence. The periodontal wound 
consists of two margins, the mineralized root surface and the connective tissue of the 
gingival flap. The root surface has been scaled and planed in order to provide a surface 
free of bacterial colonization and therefore compatible with reattachment. The first step in 
healing is the formation of a blood clot at the interface between the tooth and the gingival 
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flap [69]. A fibrin clot is developed on the tooth surface within minutes. The blood clot 
(platelets and fibrin) is responsible for providing a scaffold to begin tissue regeneration 
and to release growth factors such as platelet-derived growth factor (PDGF), insulin-like 
growth factor (IGF), and transforming growth factor (TGF) [70]. These factors are 
critical for recruiting and activating the cells needed for the subsequent steps in the 
regeneration process. Following the formation of the blood clot, there are two 
inflammatory phases [69]. The early phase of inflammation occurs within an hour and is 
predominated by inflammatory cells such as neutrophils and monocytes at the tooth 
surface. The cells in this phase are responsible for removing any pathogenic organisms 
and debris left in the periodontal wound. They are also responsible for releasing 
cytokines and chemokines needed to initiate the next phase. The late phase of 
inflammation occurs within 3 days and is predominated by macrophages, which further 
release growth factors [PDGF, IGF, TGF, fibroblast growth factor (FGF)] that recruit and 
activate periodontal ligament cells and osteoblasts. The effects of growth factors on 
periodontal ligament cells and osteoblast are summarized in Table 1.1.6. Regeneration of 
the periodontal ligament requires the presence of specific cells types and therefore the 
nature of the regeneration/repair process will depend on which cells populate the exposed 
root surface [71]. It appears that only cells from the periodontal ligament and not the 
gingival connective tissue or bone are capable of initiating new attachment [72, 73]. 
Using modern cell sorting technologies, periodontal ligament stem cells that can 
differentiate into cementum and collagen forming cells have been identified and 
characterized [74]. By day 7 of the regeneration process, granulation tissue has formed 
and new connective tissue attachment is visible at the tooth surface. Studies in canines 
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have shown that small periodontal wounds gain functional integrity (measured as the 
tensile strength between the tooth and gingival flap interface) by about 2 weeks [75]. 
Although periodontal ligament formation occurs and clinical attachment level is gained 
following scaling and rooting planing, there is usually not complete regeneration of the 
periodontal apparatus [76]. For example, in treating sites with a PD of 7.4 mm, there is on 
average a gain in attachment of only 1.2 mm [77]. The remaining amounts of PD 
reduction are due to a gain in recession of 2.0 mm on average. Similarly, although the 
recruitment and activation of osteoblasts would suggest regeneration of alveolar bone, 
there is actually very little, if any, hard tissue regeneration [68]. For example, one year 
after treatment, there is only, on average, 0.9% gain in radiographic bone level with most 
individuals showing no gain and some showing a loss. It is therefore evident that while 
periodontal regeneration is possible and does occur to a certain extent, this process is 
limited and does not completely restore the periodontium to its pre-periodontal disease 
state. Thus, current periodontal research is seeking ways to enhance and optimize the 
regeneration process.    
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Figure 1.4. Periodontal regeneration 
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Table 1.1 The effects of growth factors on osteoblast and periodontal ligament cells 
Growth Factor Source Effects on Osteoblasts Effects on Periodontal 
Ligament Cells 
PDGF Platelets 
Endothelial cells 
Smooth muscles 
Macrophages 
Fibroblasts 
á Chemotaxis 
á Cell division 
á Chemotaxis 
á Cell division 
IGF Macrophages 
Osteoblasts 
Plasma stored in bone 
Platelets 
á Cell division 
á Bone formation 
á DNA synthesis in 
PDL fibroblasts 
TGF Platelet α granules 
Macrophages 
Osteoblasts 
á Bone matrix 
Coupling bone 
resorption with 
deposition 
á Cell division 
(weakly) 
FGF Macrophages 
Osteoblasts 
Bone 
Regulation á Chemotaxis 
á Cell division 
 
 1.1.6.2 Periodontal Repair 
 The American Academy of Periodontology defines repair as “Healing of a wound 
by tissue that does not fully restore the architecture or the function of the part” [66]. In 
periodontal repair there is healing that takes place (reduction in probing depth) but with 
less gain in clinical attachment. Periodontal repair is characterized by the formation of a 
long junctional epithelium [78]. The epithelial cells of the gingival flap will migrate 
apically (toward the root) along the instrumented root surface essentially blocking 
periodontal regeneration. It was eventually determined that epithelial migration results 
when there is disruption of the fibrin clot [79]. This has lead to the belief that periodontal 
repair happens in place of regeneration under non-ideal conditions such as wound 
instability and population of the wound by the wrong cell types.  
 
	   22	  
1.1.6.3 Healing and Inflammation 
 Inflammation has important implications for wound healing. In cutaneous 
wounds, there is significant evidence suggesting that inflammation negatively affects the 
quality of wound healing. For example, fetal wounds are characterized by an absence of 
inflammation and they heal without the formation of scar tissue [80]. When inflammation 
is induced in the fetal wound, the wound then heals with formation of scar tissue.  
Impaired wound healing in the presence of inflammation is thought to occur due to an 
imbalance in proteolytic activity and oxidative stress. Chronic wounds have higher levels 
of MMP-1, MMP-2, MMP-3, MMP-8, MMP-9 and MMP-11 [81, 82] and higher levels 
of neutrophil-derived serine proteases such as cathepsin G, urokinase-type plasminogen 
activator and neutrophil elastase [83]. These proteases are detrimental to wound healing 
as they degrade extracellular materials such as fibronectin and vitronectin [84]. Proteases 
also degrade important healing growth factors such as vascular endothelial growth factor 
[85]. Therefore, in order to shift the balance toward healing and tissue formation, the 
destructive forces caused by inflammation need to be minimized. Thus, the resolution of 
inflammation is crucial for healing to occur. Although most of the evidence for this 
relationship is derived from studies in cutaneous wounds, the healing processes 
underlying the healing of oral wounds are generally quite similar [86]. The mechanisms 
of periodontal healing impaired by inflammation have not been specifically studied 
because the cause of the periodontal wound is inflammation itself and it is therefore 
obvious that a reduction in inflammation is needed for healing to occur. One recent 
abstract however has reported that periodontal ligament cells in vitro have reduced 
proliferation and adhesion in the presence of inflammation [87]. It is therefore evident 
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that the resolution of inflammation should be an effective way to promote periodontal 
healing. Future research in this area will likely focus on anti-inflammatory agents that can 
be delivered alongside conventional periodontal therapy in order to optimize periodontal 
healing.  
 
1.1.7 Importance of Successful Periodontal Therapy 
If sanative therapy is not successful, soft and hard tissue destruction will continue 
and patients with periodontitis will ultimately end up losing their teeth. Tooth loss has 
profound effects that extend beyond oral health. Firstly, tooth loss is associated with 
poorer nutritional status [88-93]. Individuals, especially older ones, with fewer teeth 
consume less protein, less fruits and vegetables and are more likely to be underweight. 
Tooth loss is also associated with lower quality of life scores [94]. As the number of 
natural teeth decrease, individuals score worse on the Oral Health Impact Profile (OHIP), 
a tool that documents the functional and psychosocial impacts of oral health disorders and 
assesses issues such as pain, problems with eating and sleeping, concerns about 
appearance and difficulties in social situations. Lastly, in some populations, tooth loss has 
even been associated with increased risk of total mortality and death from upper 
gastrointestinal cancer, heart disease, and stroke [95, 96].  
The benefits of successful periodontal therapy also extend beyond the prevention 
of tooth loss as numerous systemic health benefits have been reported [97]. Current 
evidence suggests that periodontal intervention may improve glycemic control in 
diabetics, reduce systemic markers of inflammation, lower cholesterol levels 
and improve vascular endothelial function. Due to the similar inflammatory mechanisms 
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underlying the pathogenesis of periodontal disease and many other chronic diseases such 
as diabetes, osteoporosis, cardiovascular disease, respiratory diseases, rheumatoid 
arthritis and obesity, there exists great potential for periodontal therapy to modulate these 
complex relationships [98].  
 Nutrition and diet may also play an important role in ensuring the success of 
periodontal therapy. There is growing evidence that diet and nutritional supplement use 
can optimize periodontal outcomes after sanative therapy. The remaining portions of the 
literature review will focus on this evidence supporting a link between nutrition, 
periodontal health and periodontal healing after therapy.  
 
1.2 Nutrition and Periodontal Disease  
In recent years, researchers and clinicians have begun to better understand the role 
of nutrition in periodontal health. A number of studies have uncovered relationships 
between specific nutrients and risk of periodontal disease. A small number of studies 
have also looked at the relationship between diet and periodontal status in a clinical 
population or the relationship between diet and periodontal therapy [99]. Based on the 
current literature, three nutrients that might have important clinical implications are 
vitamin C, vitamin D and omega-3 fatty acids. Though other nutrients have been 
investigated in isolated studies, these three form the majority of the research concerning 
nutrition and periodontal disease. Firstly, each has been associated with reduced risk for 
periodontal disease in the general population [100-102]. This means that they play a 
protective role in periodontal health and may be useful in helping patients who have 
undergone periodontal treatment to maintain their periodontal health in the long-term. 
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Secondly, vitamin C, vitamin D and omega-3 fatty acids might improve healing after 
periodontal procedures. Thus, they may be useful adjuncts to optimize periodontal 
treatment procedures such as sanative therapy. Each of these nutrients will be reviewed in 
sections 1.2.1, 1.2.2, and 1.2.3, respectively. 
 
1.2.1 Vitamin C  
Vitamin C is a water-soluble vitamin found primarily in fruits and vegetables. 
Plants and animals synthesize vitamin C from glucose; however, humans, primates and 
guinea pigs have lost the ability to synthesize vitamin C due to a non-functional gene for 
the L-gulonolactone oxidase enzyme (required for the final step in vitamin C synthesis), 
making dietary vitamin C intake essential. Vitamin C is absorbed in the small intestine by 
sodium dependent vitamin C transporters (SVCTs) and is transported unbound in the 
bloodstream. Vitamin C is not stored in high amounts in the body and excess is excreted 
in the urine. Therefore, plasma vitamin C levels tend to reflect recent intake and are not 
necessarily a good measure of usual vitamin C intake. However, fasting plasma vitamin C 
can indicate short-term vitamin C status, especially at lower intakes. Plasma vitamin C 
levels are considered adequate when > 28 micromole/liter (µmol/L), suboptimal when 11-
28 µmol/L and deficient when < 11µmol/L. Plasma vitamin C, however, is not strongly 
associated with vitamin C intake at higher levels of intake, especially through 
supplements, because a plateau in plasma vitamin C is achieved. The recommended 
dietary allowance (RDA) for vitamin C is 90 milligrams (mg) per day for males and 75 
mg/day for females over 19 years of age. The RDA for smokers also calls for an 
additional 35 mg of vitamin C per day due to the oxidative stress caused by smoking. 
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 Vitamin C is an essential cofactor for α-ketoglutarate-dependent dioxygenases 
such as prolyl hydroxylases, which are needed for the biosynthesis of collagen [103]. 
Vitamin C also provides protection against oxidative stress-induced cellular damage by 
acting as a water-soluble endogenous antioxidant. Vitamin C will readily donate an 
electron to potentially damaging oxidizing radicals such as hydroxyl radical [HO•], 
alkoxyl radical [RO•], peroxyl radical [LOO•], thiol radical [GS•], and tocopheroxyl 
radicals [TO•] [104]. The resulting ascorbate radical is relatively unreactive and can be 
reduced back to vitamin C by NADH/NADPH dependent reductases or pH-dependent 
disproportionate reactions.  
The relationship between vitamin C and oral health has been known since the start 
of the twentieth century when vitamin C deficiency was determined to be the causative 
agent of scurvy [105]. Vitamin C may play a duel role in periodontal health. Firstly, 
because vitamin C is an antioxidant, it may help attenuate the oxidative stress associated 
with periodontitis. Secondly, because vitamin C is essential for collagen formation, it 
might promote healing and regeneration of soft tissues after periodontal procedures.   
 
1.2.1.1 Vitamin C and Periodontal Disease Risk  
Data from NHANES III has shown a relationship between reduced dietary 
vitamin C intake and increased risk for periodontal disease in the general population 
[100]. The odds ratios (OR) for having periodontal disease  (defined as having a mean 
CAL ≥ 1.5 mm) after adjusting for age, gender, smoking, and bleeding was 1.30, 1.26, 
1.21 and 1.16 for subjects who consumed 0-29 mg, 30-59 mg, 60-99 mg, and 100-179 mg 
of dietary vitamin C per day respectively. Also, when vitamin C intake was used as a 
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continuous predictor, the odds ratio was 1.21 for current smokers, 1.28 for former 
smokers and 1.06 for non-smokers indicating a higher risk for smokers and former 
smokers with lower vitamin C intakes.  To compare with dietary recommendations, 
increased periodontal disease risk was most apparent in individuals who had intakes well 
below the RDA (75 mg/day for females and 90 mg/day for males).  Smokers would be 
even further from meeting the RDA as they require an additional 35 mg/day of vitamin C. 
Thus, risk seems to be conferred in this case by deficiencies in vitamin C intake. At risk 
individuals must have been consuming very few fruits and vegetables as the RDA can be 
met with a few commonly consumed fruits and vegetables (1/2 cup of orange juice has 66 
mg, 1/2 a grapefruit has 47 mg, a medium potato has 27 mg and 1/2 cup of cooked 
peppers has > 100 mg) [106]. 
Three related studies have investigated the relationship between dietary vitamin C 
intake, serum ascorbic acid and periodontal disease risk in an elderly Japanese population 
[107-109]. Compared to individuals consuming 22-80 mg of vitamin C a day, those 
consuming 81-100 mg and 101-196 mg had incident rate ratios of 0.76 and 0.72, 
respectively, for periodontal disease progression (defined as having ≥ 3 mm of 
attachment loss over the two year study period) [109]. In the same population, there was 
also a small but significant correlation (r = -0.23) between fasting serum ascorbic acid 
levels and clinical attachment loss [107]. Similarly, when participants were classified into 
tertiles of ascorbic acid levels, those in the middle [5.9-8.9 micrograms (µg) per milliliter 
(mL)] and lowest (0.2 -5.9 µg/mL) tertiles had relative risks of 1.12 and 1.30 respectively 
for periodontal disease progression compared to those in the highest tertile (8.5-22.6 
µg/mL) [108].  
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  Another small study in Amsterdam found that plasma ascorbic acid was lower in 
patients with periodontitis compared to controls matched for age, gender, race and 
smoking habits (8.3 vs. 11.3 mg/l) [110]. They also observed an inverse relationship 
between polymorphonuclear neutrophilic leucocyte ascorbic acid levels and probing 
depth. Since the amount of vitamin C in neutrophils (as opposed to plasma levels) is 
associated with disease severity (probing depth), this suggests that the relationship 
between vitamin C and periodontal disease is at least in part mediated by the amount of 
vitamin C in these cells, which have a higher antioxidant demand due to the oxidizing 
environment they create during inflammatory processes.  
 
1.2.1.2 Human Intervention Studies for Periodontal Health 
In a case-matched study, patients with gingivitis (and who were vitamin C 
sufficient) receiving professional cleaning were given 1000 mg of ascorbic acid daily for 
6 weeks. No significant differences were observed in probing depth, attachment level, 
gingival inflammation, and plaque level [111]. The lack of effect may be due to the fact 
that patients were vitamin C sufficient at baseline or that patients with gingivitis do not 
have enough periodontal tissue destruction to see a benefit from extra vitamin C.  
Two unique studies using chewing gum or whole food, however, have shown 
more promising results with vitamin C supplementation. In one study, healthy patients 
who tend to form calculus received 60 mg of vitamin C in sugar free chewing gum 5 
times daily for 3 months [112]. Vitamin C gum chewers showed a reduction in the 
number of bleeding sites while the non-vitamin C chewers did not. In the other study, 
patients with chronic periodontitis were given 2 grapefruits daily for 2 weeks, which 
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resulted in increased serum vitamin C, a lower sulcus-bleeding index, but no difference in 
probing depth and plaque index [113]. The effects may be due to vitamin C but they 
could also be due to a number of other bioactive compounds found in grapefruit, which 
might have antioxidant activity [114]. 
 
1.2.1.3 Human Intervention Studies for Periodontal Healing 
In a recent study, patients undergoing non-surgical periodontal therapy were given 
2000 mg of vitamin C for 4 weeks and then re-examined at 1 and 3 months post-
treatment [115]. There were no significant differences in PD, CAL or BOP between the 
treatment and control group but this may have been due to a small sample size (n = 15), a 
short intervention period and because the authors failed to control for the baseline 
probing depth and clinical attachment loss of patients.  
 
1.2.1.4 In Vitro and Animal Experiments  
Recent cell culture work has shown that vitamin C can induce periodontal 
ligament progenitor cells (a type of mesenchymal stem cell) to differentiate into 
osteoblasts (a bone forming cell) [116]. These findings have highlighted the potential use 
of ascorbic acid in regenerative medicine and dentistry. Although vitamin C has 
traditionally been thought of as a modulator of ROS and soft tissue formation, it may also 
play a role in hard tissue formation although we do not know the relevance of these 
findings in vivo.  
One study in animals supports a role for vitamin C in promoting soft tissue health. 
During natural aging in Wistar rats, vitamin C supplementation (1g/L in drinking water) 
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increased the number of type 1 collagen fibres resulting in a thicker, healthier periodontal 
ligament at 14 months of age [117].   
  
 To summarize, vitamin C intake and vitamin C status have consistently been 
associated with risk for periodontal disease, while results from clinical trials are mixed. 
As vitamin C is an important antioxidant and essential cofactor, a plausible mechanistic 
link exists between this nutrient and periodontal disease risk and possibly periodontal 
healing. Vitamin C is therefore an excellent candidate to investigate as a potential 
modulator of healing following sanative therapy.   
 
1.2.2 Vitamin D 
Vitamin D is a fat-soluble vitamin that has been associated with numerous health 
outcomes. Vitamin D is synthesized in the skin upon expose to ultraviolet light. It is also 
obtained in the diet though few foods are high in vitamin D. Fatty fish, eggs, fortified 
milk and margarine are among the few foods that provide a significant amount of vitamin 
D. Vitamin D is transported through the blood stream primarily bound to the vitamin D 
binding protein and is carried to the liver where it is converted to 25-hydroxyvitamin D 
(25(OH)D). 25(OH)D has a half-life of about 3 weeks and is thus used as the standard 
biomarker of vitamin D status [118]. 25(OH)D eventually undergoes a second 
hydroxylation to 1,25-dihydroxyvitamin D [1,25(OH)2D], which is the active form of 
vitamin D. This activation step is performed by the enzyme 1α-hydroxylase, which is 
expressed in many tissues including the kidneys, skin, lungs, breast, intestine, prostate, 
endocrine glands, cells of the immune system (macrophages, T cells, B cells, dendritic 
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cells), osteoblasts and chondrocytes [119]. The half-life of 1,25(OH)2D is about 4 hours 
and its levels are regulated hormonally according to the calcium needs of the body. 
Vitamin D works by binding to nuclear receptors and modulating gene expression. The 
classical role of vitamin D is to regulate calcium levels by increasing intestinal 
absorption, kidney reabsorption and bone release of calcium. Vitamin D, along with 
calcium is therefore critical in the prevention of skeletal disorders such as rickets, 
osteomalacia and osteoporosis. Vitamin D metabolism is outlined in Figure 1.2.2.  
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Figure 1.5 Vitamin D metabolism. 
The classical role of 1,25-dihydroxyvitamin D is depicted on the left side of the figure 
where 1,25-dihydroxyvitamin D is produced in response to low calcium resulting in 
increased intestinal absorption, kidney reabsorption and bone resorption. The right side of 
the figure depicts the immunomodulatory effects of 1,25-dihydroxyvitamin D.  1,25-
dihydroxyvitamin D can enhance antibacterial activity in periodontal cells and innate 
immune cells, as well as inhibit inflammation from the adaptive the adaptive immune 
system. Lines ending with an arrow indicate a stimulatory effect while lines ending with 
an “X” indicate an inhibitory effect. 
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The RDA for vitamin D for males and females age 19-70 is 600 international 
units (IUs)/day and 800 IU/day for older individuals [120]. Health Canada states that 
most individuals have sufficient vitamin D when their serum 25(OH)D is 50 nmol/L [20 
ng/mL] or greater. Symptoms of severe deficiency such as rickets and osteomalacia 
appear when serum 25(OH)D levels are below 30 nmol/L [12 ng/mL]. The exact cut-off 
for vitamin D sufficiency, however, is currently under debate. Many researchers believe 
that 25(OH)D levels should be at least 75 nmol/L (30ng/mL) to promote multiple health 
outcomes including fewer falls, better tooth attachment, less colorectal cancer, improved 
depression and wellbeing [121]. This debate largely stems from epidemiological evidence 
and will likely not be resolved until human clinical trials are completed. Nonetheless, 
some organizations such as the Canadian Cancer Society and Osteoporosis Canada 
recommend people take 1000 IU of vitamin D a day [122, 123].   
Recent enthusiasm in vitamin D now stems from our understanding of its extra 
skeletal effects. For example, vitamin D has come to be known as an anti-inflammatory 
agent due to its ability to regulate both the innate and adaptive immune systems [124]. 
Vitamin D has several innate immune targets. Firstly, when bacterial pathogens are 
detected via toll like receptor on myeloid cells, there is an up regulation of 1α-
hydroxylase (the enzyme that converts 25(OH)D to 1,25(OH)2D, which is the active form 
of vitamin D).  Activated vitamin D has been shown to enhance antimicrobial activity by 
inducing expression of beta defensins [125] and cathelicidins [126] in cells such as 
monocytes and neutrophils. These molecules help eliminate bacterial pathogens by 
destabilizing their cell membranes. By enhancing the innate immune response to 
pathogens, they are more quickly eliminated, which reduces the amount of chronic 
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bacterial exposure. Another important innate target of vitamin D is the dendritic cell, a 
cell type that is crucial to the coordination of the adaptive immune system with the innate 
immune system. Vitamin D has been shown to enhance the tolerogenic properties of 
myeloid dendritic cells by allowing them to preferentially recruit regulatory T cells [127]. 
Vitamin D also has direct effects on the adaptive immune system by acting specifically 
on B and T cells. In B cells, vitamin D can inhibit the generation of memory and plasma 
B cells and promote the apoptosis of immunoglobulin-producing B cells [128]. T cells 
constitute a diverse population but in general vitamin D acts on T cells by inhibiting the 
production of pro-inflammatory Th1 cytokines (IL-2, INF-γ, TNF-α) and promoting the 
production of more anti-inflammatory Th2 cytokines (IL-3, IL-4, IL-5, IL-10) [129].  
As the immunomodulatory effects of vitamin D have been well documented, 
vitamin D may play a duel role in periodontal health by enhancing the initial immune 
attack against pathogenic organisms and by modulating the immune response in order to 
minimize chronic inflammation. In addition, since the resolution of inflammation is vital 
to periodontal healing, vitamin D may also enhance healing after periodontal therapies by 
acting as an anti-inflammatory agent.   
 
1.2.2.1 Vitamin D and Periodontal Disease Risk 
Two large cross sectional studies using NHANES III data have looked at the 
relationship between 25(OH)D and periodontal disease. The first found an inverse 
relationship between serum 25(OH)D and clinical attachment loss in men and women 
over 50 years of age [101]. Men with serum 25(OH)D levels 40.4-53.7 nmol/L and < 
40.4 nmol/L had 0.23 mm and 0.39 mm more attachment loss respectively compared to 
	   35	  
men with serum 25(OH)D ≥ 85.6 nmol/L. Women with serum 25(OH)D levels < 40.4 
nmol/L had 0.26 mm more attachment loss compared to women with serum 25(OH)D ≥ 
85.6 nmol/L. There was no relationship between attachment loss and serum 25(OH)D for 
subjects under 50 years of age. The fact that the relationship was apparent only in 
individuals over 50 years of age may be because periodontal disease is more prevalent in 
older populations. The second study found that subjects that have never smoked in the 
highest quintile of serum 25(OH)D (average 106 nmol/L) were 20% less likely to bleed 
on probing [130].  
Two studies have also investigated the relation between 25(OH)D and periodontal 
disease risk specifically among postmenopausal women. The first found that 
postmenopausal women who were vitamin D sufficient (>50 nmol/L) had 33% lower 
odds of having periodontal disease [131]. The second study used NHANES III data to 
look at the interaction of hormone replacement therapy (HRT) and vitamin D [132]. They 
found decreased odds of moderate to severe periodontitis among HRT users who were 
vitamin D sufficient (>50 nmol/L). They hypothesize that vitamin D enhances the anti-
inflammatory effects of estrogen and progesterone.  
There are a couple of studies that investigated vitamin D intake in patients with 
periodontal disease. In the first, the use of calcium and vitamin D supplements was 
investigated among older patients (50 years of age and older) who had previously 
undergone periodontal treatment and were on maintenance therapy. Those who took 
calcium and vitamin D supplements (at least 1000 mg calcium and 400 IU vitamin D) 
daily for at least 18 months showed a trend for shallower probing depths, fewer bleeding 
sites, lower gingival index values, fewer furcation involvements, less attachment loss, and 
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less alveolar crest height loss compared to those not taking such supplements but the 
results were not significant [133].  
  The second study investigated vitamin D status in relation to healing after 
periodontal therapy. This study found that patients with severe periodontitis undergoing 
open flap debridement surgery who were vitamin D sufficient (>50 nmol/L) had better 
clinical attachment level gain and probing depth reduction [134]. Although these results 
are promising, the study had a very small sample size (n = 7) and the findings are 
compounded by the fact that more than half of the vitamin D deficient group were 
smokers. Study after study show that smokers have compromised healing after 
periodontal treatment resulting in less attachment gain and less probing depth reduction 
[33]. Therefore, the impaired healing seen in the vitamin D deficient group may be 
exaggerated due to the effects of smoking. These findings need to be replicated by 
analyzing smokers and non-smokers separately to determine if impaired healing is 
associated with vitamin D status rather than smoking status.   
 
1.2.2.2. Vitamin D Intervention Studies in Humans 
Two vitamin D intervention studies whose primary outcome was to measure bone 
loss at non-oral sites (whole body, hip and spine) have provided valuable insight into the 
relationship between vitamin D, calcium and tooth loss. The first study investigated tooth 
loss in postmenopausal women. It was found that neither 400 IUs of vitamin D with 377 
mg of calcium daily for 1 year or 700 IUs of vitamin D with 500 mg of calcium daily for 
2 years could reduce the incidence of tooth loss [54]. However, a similar study where 
elderly subjects (≥ 65 years of age) received 700 IUs of vitamin D and 500 mg of calcium 
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daily for 3 years found there were lower odds of tooth loss in the treatment group but 
with no differences in probing depth [135]. These findings suggest a role for vitamin D in 
alveolar bone maintenance. To our knowledge, there are currently no intervention studies 
with vitamin D in patients with periodontal disease.   
 
1.2.2.3 In Vitro and Animal Experiments  
In the last few years, advances in basic science have helped uncover a potential 
role for vitamin D in the periodontium. First, it is now known that gingival fibroblasts 
and periodontal ligament cells express 1α-hydroxylase, enabling them to locally generate 
the active form of vitamin D [136]. Notably, vitamin D has been shown to enhance the 
innate immune response to Aggregatibacter actinomycetemcomitans (a periodontal 
pathogen) by increasing the expression of innate immune genes such as LL-37, CD14, 
TREM-1 and IL-8 in human gingival epithelial cells [137]. In contrast though, vitamin D 
has been shown to decrease IL-8 expression in response to Porphyromonas ginigivalis 
bacteria in human periodontal ligament cells [138]. Based on the limited number of 
studies, it is clear that more research is needed to determine the direct effects of vitamin 
D on the periodontium.  
Few studies have looked at vitamin D in animals with experimental periodontitis. 
One group studying diabetic mice with periodontitis have found that 25(OH)D injections 
lowered fasting glucose levels, glycosylated hemoglobin, serum TNF-α levels, and 
decrease alveolar bone loss [139, 140]. These findings have not yet been replicated in 
non-diabetic mice with periodontitis.  
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To date, there is potential for vitamin D to play a significant role in periodontal 
health. The associations between vitamin D and periodontal health have been well 
documented and there exists plausible mechanistic links showing its immune enhancing 
activity and anti-inflammatory activity. Based on the current literature, there is a need for 
more studies to determine if vitamin D can be useful for maintaining periodontal health 
and promoting healing after periodontal therapies.    
 
1.2.3 Polyunsaturated Fatty Acids   
 Omega-6 and omega-3 polyunsaturated fatty acids (PUFAs) are essential fats that 
must be obtained from the diet [141]. Linoleic acid (LA) is the primary omega-6 PUFA 
and α-linolenic acid (ALA) is the primary omega-3 PUFA obtained in the diet. The RDA 
for LA is 17 g/day (males 19-50), 14 g/day (males 51+), 12 g/day (females 19-50) and 11 
g/day (females 51+), while the RDA for ALA is 1.6 g/day for males 19+ and 1.1 g/day 
for females 19+. LA and ALA can be converted to longer chain fatty acids. LA can be 
converted to arachidonic acid (AA), while ALA can be converted to eicosapentanoic acid 
(EPA) and docosahexanoic acid (DHA). The conversion of ALA into EPA or DHA, 
however, is very low in humans ranging from 1% to 10% [142]. Substantial levels of 
EPA and DHA can only be obtained by eating fatty fish, certain seafood or taking dietary 
supplements. Currently, Health Canada does not have an RDA for EPA and DHA.   
 EPA and DHA have received a significant amount of attention due to a number of 
purported health benefits. They are most notably known for their cardio-protective 
effects: decreases in blood pressure, inflammation, triglycerides, insulin resistance, and 
improved vascular function [143]. However, EPA and DHA may be efficacious in 
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improving or preventing a number of health conditions such as obesity, metabolic 
syndrome [144], osteoporosis [145], rheumatoid arthritis [146] and cancer [147], 
although these relationships continue to be studied. Many of the health benefits of EPA 
and DHA are likely due to their ability to modulate inflammation. Long chain fatty acids 
are incorporated into cell membrane phospholipids and serve as precursors for 
eicosanoids. AA and EPA are converted by phospholipase A2, cyclooxygenase (COX) 
and lipooxygenase (LOX) to eicosanoids such as prostaglandins (PG), thromboxanes 
(TX), leukotrienes (LT) and hydroxyl-fatty acids [148]. In general, AA-derived 
eicosanoids are pro-inflammatory while those derived from omega-3 long chain fatty 
acids are less inflammatory (but not always).  It has also been shown that EPA and DHA 
are precursors for a number of biologically active agents such as resolvins, protectins and 
mareins [149], which help resolve inflammation by inhibiting the production of 
inflammatory cytokines and decreasing leukocyte recruitment. Omega-6 and omega-3 
PUFA metabolism is illustrated in Figure 1.2.3. Because omega-6 and omega-3 fatty 
acids are metabolized through similar pathways, the ratio of omega-6 to omega-3 may be 
an important determinant of inflammation. In today’s Western diet, a ratio of omega-6 to 
omega-3 ratio of 15:1 may promote the development of a number of chronic diseases 
[150]. In contrast for example, a lower ratio of 4:1 has been associated with a 70% 
decrease in risk for total mortality from cardiovascular disease [151]. Current Health 
Canada recommendations for the ratio of omega-6 to omega-3 fatty acids is 
approximately 10:1, which falls between these two extremes. 
 There are exceptions to the general trend of omega-6 PUFA being pro-
inflammatory. Gamma-linolenic acid (GLA), for example, is an omega-6 PUFA that is 
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thought to have anti-inflammatory properties. GLA is believed to compete with AA to 
form the less saturated prostaglandin E1 resulting in reduced production of AA derived 
metabolites [152]. In vitro, GLA has been shown to suppress superoxide generation [153] 
and inflammatory cytokine production [154].  
 Due to their anti-inflammatory properties, there exists a plausible link between 
omega-3 PUFA intake and periodontal disease. In fact, there are a number of studies 
demonstrating this relationship and there have even been a few successful intervention 
studies using these nutrients to manage periodontal disease.  
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Figure 1.6 Omega-6 and omega-3 PUFA metabolism (modified from Albertazzi and 
 Coupland, 2002 [155]). Abbreviations: AA (arachidonic acid), EPA 
 (eicosapentaenoic acid), DHA (docosahexaenoic acid), LOX (lipooxygenase), 
 COX (cyclooxygenase), LT (leukotriene), TX (thromboxane), PG (prostaglandin), 
 Rv (resolvin). A line ending in an arrow indicates a stimulatory effect while a line 
 ending in an “X” indicates an inhibitory effect. A hatched line indicates a weaker 
 effect compared to a solid line.  
 
 
1.2.3.1 PUFAs and Periodontal Disease Risk   
Data from NHANES III has been used to examine the relationship between 
omega-3 PUFAs and periodontal disease risk. It was found that subjects who consumed 
0-40 mg/day and > 40 mg/day of DHA had 0.80 and 0.69 odds ratio, respectively, of 
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any one tooth) compared to those who did not consume any DHA [102]. However, there 
were no associations with EPA or ALA intake. Interestingly, the associations remained 
consistent even when those taking PUFA supplements were excluded from the analysis.  
 A couple of prospective studies have investigated PUFA intake in relation to 
periodontal disease in an elderly Japanese population. In one study, those in the lowest 
tertile of DHA intake had increased incidence of periodontal progression (incidence rate 
ratio = 1.49) but no associations were found with EPA [156]. A second study found that 
those in the highest tertile of total omega-6 fatty acids compared to total omega-3 fatty 
acids intake (ratios 4.02:1 – 5.67:1) were at a greater risk of periodontal disease events 
(measured as number of sites with CAL >3 mm) [157].  The highest tertile of omega-
6/omega-3 in this study is still quite low compared to North American diets (~15:1) 
making it difficult to know if these findings could be replicated in a North American 
population.  
 
1.2.3.2 PUFA Intervention Studies in Humans 
 To date, only a couple of small intervention studies have been performed in 
humans, but with promising results. In a pilot study, adults with periodontitis received 3 g 
of fish oil (~ 390 mg EPA and 540 mg DHA), or 3 g of borage oil (~ 600 mg GLA, an 
omega-6 PUFA) or 1.5 g of each for 12 weeks. Interestingly, improvements in probing 
depth and gingival inflammation were seen in the borage oil group, while only a trend for 
improvement was seen in the fish oil and combination groups [158]. These findings are 
quite impressive as the sample size was quite small (n = 5-7) and improvements were 
seen without the use of adjunctive periodontal therapy. 
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In another promising study, patients undergoing sanative therapy were 
supplemented with fish oil (900 mg/day EPA + DHA) and low dose aspirin (81 mg/day) 
for six months. The treatment group had significantly fewer deep pockets at 3 and 6 
months compared to the control group and significantly lower levels of salivary RANKL 
and MMP-8 at 6 months [159]. It will be interesting to see if these results can replicated 
using fish oil alone without low dose aspirin.  
 
1.2.3.3 In Vitro and Animal Studies  
 Diets rich in omega-3 PUFA have been found to be beneficial in animals with 
experimental periodontitis. A fish oil diet reduces expression of IL-1β and TNF-α and 
increases expression of antioxidant enzymes (catalase and superoxide dismutase) in 
gingival tissue of rats treated with Porphyromonas gingivalis [160]. Administration of 
EPA and DHA has also been shown to inhibit MMP-8 expression in gingival tissue of 
rats treated with E.coli endotoxin [161]. Furthermore, omega-3 PUFA rich diets have 
been shown to decrease alveolar bone loss in both rat [162] and mouse [163] models of 
periodontitis.  
 One group has been able to demonstrate direct effects of omega-3 PUFA 
metabolites in periodontal biopsies [164]. They have shown that treatment of periodontal 
ligament cells and monocytes with resolvin D1, a downstream metabolite of DHA, can 
inhibit production of prostaglandin E2 and up regulate production of lipoxin A4. This 
ultimately resulted in increased periodontal ligament fibroblast proliferation and wound 
closure. 
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 In summary, intakes of EPA and DHA show promise as potential modulators of 
periodontal healing. Like vitamin C and vitamin D, intakes of long chain omega-3 PUFA 
have been associated with reduced risk of periodontal disease. EPA and DHA 
intervention studies, though only pilot studies, also show promising results. Mechanistic 
studies suggest that EPA and DHA modulate healing, as they are required for the 
resolution of inflammation. Their use to optimize periodontal outcomes after sanative 
therapy warrants further investigation.     
 
1.3 Summary and Rationale 
 All of the available studies linking vitamin C, vitamin D and omega-3 PUFAs to 
periodontal health and periodontal healing are summarized in Table 1.2. There exists a 
substantial amount of evidence demonstrating a link between lower risk of periodontal 
disease and higher intakes of vitamin C, vitamin D and DHA. It is clear from the 
epidemiological studies that higher intakes of these nutrients are associated with 
decreased risk of periodontitis. Interestingly, protective levels are often higher than 
current recommendations. For example, in the NHANES studies, vitamin C intakes >180 
mg/day (compared to the RDA of 75 or 90 mg/day) were the most protective [100]. 
Similarly, serum 25(OH)D levels ≥ 85 nmol/L (compared to Health Canada’s 50 nmol/L 
cut-off) were the most protective [101]. Fortunately since higher DHA intakes (≥ 0.04 
g/day) have been associated with reduced incidence of periodontal disease [102], 
Canada’s Food Guide recommendation to consume two servings of fish per week [165] 
should easily help individuals meet these levels. For example, two 75.0 g servings of 
salmon (approximately the size and thickness of the palm of a hand) a week would 
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provide approximately 2 g of DHA resulting in an average daily intake of approximately 
0.30 g/day.  
 Despite these links, very few studies, if any, have properly investigated the 
relationship between vitamin C, vitamin D, omega-3 PUFAs and periodontal outcomes 
after sanative therapy. There is the study by Bashutski et al. [134] showing improved 
healing when patients are vitamin D sufficient. However, study design issues such as 
small sample size (n = 7) and lack of control for important confounders (i.e. smoking) 
casts doubt on the significance of these findings.  
 There is also currently a lack of clinical intervention studies with vitamin C, 
vitamin D and omega-3 PUFAs in patients undergoing periodontal disease treatment. 
Only one intervention study with vitamin C has been reported and it did not find any 
benefit in PD, CAL or BOP after sanative therapy [115]. However, this study had a small 
sample size (n = 15), a short follow-up time (1 month) and most importantly, failed to 
control for outcomes at baseline. There are currently no intervention studies with vitamin 
D. There is also only one study looking at omega-3 PUFA supplementation in 
conjunction with sanative therapy [159]. Although this study had positive results, the 
omega-3 PUFAs were administered with low dose aspirin and therefore we do not know 
the unique impact of the omega-3 PUFAs. 
 Nonetheless, the animal and cell culture studies do suggest that these nutrients 
will be able to promote periodontal health and improve healing after periodontal therapy. 
Vitamin C may reduce oxidative stress and promote collagen synthesis in order to repair 
the periodontal ligament. Meanwhile, vitamin D and omega-3 PUFAs may help resolve 
inflammation in order to allow healing to occur. The potential mechanisms by which they 
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might optimize periodontal healing are illustrated in Figure 1.3. These hypothesized 
mechanisms are based on the idea that they will promote healing by tilting the balance 
between destruction and repair toward the repair processes. By helping to fight infection 
and minimize chronic inflammation, they help reduce the amount of periodontal 
destruction. Similarly, by reducing inflammation, they may allow healing to proceed 
because healing cannot take place as long as inflammatory destruction is still occurring. 
Lastly, nutrients like vitamin C and D may further favor a balance toward healing by 
enhancing the regenerative processes of soft and hard tissue formation.       
 Due to the potential of vitamin C, vitamin D and omega-3 PUFAs to help resolve 
periodontitis and promote healing after sanative therapy, we propose a study to 
investigate the relationship between intakes of these nutrients and periodontal status, 
specifically PD, after sanative therapy.  
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Table 1.2 Summary of available studies. The numbers of studies in each area of research 
are listed along with the main findings of the studies.  	   Vitamin C	   Vitamin D	   EPA and DHA	  
Association 
Studies	  
- 5 studies  
(á Risk of having 
periodontal disease 
with low intakes of 
vitamin C and low 
ascorbic acid levels)	  
- 4 studies 
(á Risk for periodontal 
disease with lower 
serum 25(OH) D) 
- 1 study on suppl. use 
in periodontal 
maintenance patients 
(trend for âPD, CAL, 
BOP)	  
- 2 studies investigating 
EPA, DHA and 
Periodontal Disease (â 
risk with áDHA intake 
but not with EPA) 
- 1 PUFA study (â risk 
of periodontal disease 
with â n-6: n-3 ratio)	  
Association 
Studies with 
Sanative Therapy	  
- None	   - 1 study in patients 
undergoing open flap 
debridement (patients 
with 25(OH)D ≥ 50 
nmol had á PD and 
CAL reduction) 	  
- None	  
Intervention 
Studies	  
- 2 studies, one with 
vitamin C chewing 
gum and one with 
grapefruit 
(Both showed â 
BOP)	  
-3 tooth loss studies  
(one found that 
individuals ≥ 65 taking 
700IU vitamin D + 
500mg calcium had â 
risk of tooth loss)	  
- 1 study where 
periodontal patients 
received 3000 mg/d of 
fish oil for 12 weeks 
(trend for âPD)	  
Intervention 
Studies with 
Sanative Therapy	  
-  1 study with 1000 
mg/d in patients with 
gingivitis 
- 1 study with 2000 
mg/d in patients with 
periodontitis 
(No effects but poor 
study designs)	  
- None	   - 1 study with fish oil 
(900 mg EPA and 
DHA) + low dose 
aspirin (â PD and â 
salivary RANKL and 
MMP-8)	  
Preclinical and 
Mechanistic: 
Animal Studies	  
- 1 study with 
vitamin C in drinking 
water (á periodontal 
ligament collagen 
fibers in very old 
rats)	  
- 2 studies treating 
diabetic mice with 
25(OH)D injections (â 
HbA1c, â serum TNF-
α and â alveolar bone 
loss)	  
- 4 studies with omega-
3 rich diets in rodents 
with experimental 
periodontitis (â 
gingival TNFα, IL-1β 
and MMP-8, â alveolar 
bone loss)	  
Preclinical and 
Mechanistic: Cell 
Culture Studies	  
- 1 study treating 
periodontal ligament 
progenitor cells with 
vitamin C (Induced 
differentiation into 
osteoblasts) 	  
- 1 study showing 
presence of 1α-
hydroxylase in 
periodontal cells 
 - 2 studies treating 
periodontal cells with 
vitamin D (enhanced 
response to pathogens)	  
- 1 study treating 
periodontal ligament 
cells with resolvin D1 
(â inflammation, á 
fibroblast proliferation 
and closure of 
experimental wounds)	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Figure 1.7 Potential mechanisms for improved periodontal healing after sanative therapy 
with vitamin C, vitamin D, EPA and DHA by inhibition of periodontal destruction and 
promotion of periodontal regeneration. On the left is a replicate of figure 1.3 depicting 
periodontal destruction and on the right is a replicate of figure 1.4 depicting periodontal 
regeneration.. Processes (e.g. soft/hard tissue destruction/formation) are enclosed in a box 
while cells/mediators are not enclosed. A line with an arrow indicates a stimulatory effect 
while lines ending in a bar indicate an inhibitory effect. A hatched line indicates 
intervention by sanative therapy and nutrition. Sanative therapy inhibits bacterial 
pathogens (by mechanically removing them) on the destruction side of the figure. 
Vitamin C inhibits reactive oxygen species on the destruction side and promotes collagen 
synthesis on the regeneration side. Vitamin D inhibits inflammation and periodontal 
pathogens on the destruction side and promotes bone formation on the regeneration side. 
EPA and DHA inhibits inflammation on the destruction side. 
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Chapter Two 
 
OBJECTIVES AND HYPOTHESES
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2.1 Objectives 
The main objectives of this study were to determine: 
1. if higher intakes of vitamin C, vitamin D, EPA and DHA, either through diet 
and/or supplement use, are associated with improved periodontal outcomes 
after sanative therapy;  
2. if higher serum 25-hydroxyvitamin D levels are associated with a greater 
reduction in probing depth after sanative therapy. A biomarker for vitamin D 
was deemed necessary in order to account for endogenous vitamin D synthesis 
from sunlight exposure (a phenomenon that does not occur for other 
nutrients).  
 
2.2 Hypotheses  
1. Higher intakes of vitamin C, vitamin D, EPA, DHA, either through diet and/or 
supplement use, will be associated with a greater reduction in probing depth eight 
weeks after sanative therapy. 
2. Higher serum 25-hydroxyvitamin D levels will be associated with a greater 
reduction in probing depth eight weeks after sanative therapy.  
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Chapter Three 
 
MATERIALS AND METHODS 
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3.1 Experimental Design 
This study was approved by the Human Bioscience Research Ethics Board at 
Brock University, St. Catharines, Ontario (File #12-068-Ward, Appendix 8.1). The study 
was conducted at a periodontal clinic in southern Ontario. All patients who had sanative 
therapy prescribed as part of their treatment plan were invited to participate in the study. 
Patients had moderate to severe periodontitis, defined as having ≥ 2 interproximal sites 
with PD ≥ 5 mm. No other exclusion criteria were applied. The study design is shown in 
Figure 3. Prior to enrollment, patients attended a consultation where a baseline 
periodontal examination was completed. Patients then returned approximately 2 months 
later for sanative therapy at which point they were enrolled in the study. Patients were 
given a letter of invitation (Appendix 8.2) and they signed a consent form (Appendix 
8.3). During the appointment where sanative therapy was performed, a blood sample was 
taken and body weight, height and waist and hip circumferences were measured. Patients 
were then given a food frequency questionnaire, a supplement use questionnaire and a 
physical activity questionnaire to complete at home. The physical activity questionnaire 
was administered because low levels of physical activity have been associated with 
periodontal disease and therefore physical activity is a potential confounder of the 
relationship between diet and periodontal healing.  Patients returned to the clinic 
approximately 8 weeks later for their re-exam. During their re-exam, a periodontal 
examination was performed, a blood sample was taken and body weight, height and waist 
and hip circumferences were measured. Participants were later provided with a 
personalized report containing the result of their vitamin D and dietary analyses 
(Appendix 8.8).  
	   53	  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Experimental outline 
 
 
 
3.2 Periodontal Examination 
The baseline periodontal examination was completed by one periodontist and the 
re-exam periodontal examination was completed by one of four calibrated hygienists. 
Prior to the study, the hygienists were calibrated for probing pressure. Probing pressure 
was simulated by having each hygienist probing against an electronic scale to ensure that 
they each probed with a pressure of 0.25 Newtons.  The examination included 
measurement of probing depth (PD), bleeding on probing (BOP), and plaque score. PD 
was measured using a UNC15 Probe (Hu-Friedy) at six sites per tooth (mesial buccal, 
buccal, distal buccal, mesial lingual, lingual and distal lingual) and rounded to the nearest 
millimeter. The PD of all healthy sites was estimated as 3 mm since the clinicians did not 
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routinely record the PD of healthy sites. Subsequently, an average PD was calculated for 
the whole mouth including healthy sites, which is standard in the literature. BOP was 
assessed by visual inspection after probing and is expressed as % sites with bleeding. 
Plaque score was assessed by visual inspection and is expressed as % teeth with visible 
plaque.  
 
3.3 Nutrient Intake Estimates 
To estimate daily nutrient intakes from diet, patients completed the 2005 Block 
Food Frequency Questionnaire (FFQ) at home and returned the questionnaire at their re-
exam (Appendix 8.4). The Block FFQ is a commonly used tool to estimate usual dietary 
intakes [166-168]. The 2005 Block FFQ queries 110 food items selected from the United 
States National Health and Nutrition Examination Survey (NHANES). Respondents are 
asked how often each item is consumed and to specify the portion size. Pictures are 
provided to enhance the accuracy of quantification. A series of "adjustment" questions 
are also asked to provide greater accuracy in assessing fat and carbohydrate intake [169]. 
The adjustment questions, for example, ask respondents whether or not they consume low 
fat or low carbohydrate options for foods where low fat and low carbohydrate options are 
commonly available. Nutrient intakes are then quantitatively assessed using a nutrient 
database developed from the U.S. Department of Agriculture Food and Nutrient Database 
for Dietary Studies [170]. A FFQ was used in lieu of other methods (such as a diet 
record) in order to minimize patient burden.  
Energy-adjusted nutrient intakes were then calculated using the residual method 
[171]. The use of energy-adjusted nutrient intakes has become standard in 
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epidemiological research because it minimizes reporting errors and it isolates the effect of 
a nutrient or food independent of energy intake [172, 173]. Because nutrient intakes are 
highly correlated to total energy intake, errors due to over and under reporting can be 
minimized by standardizing nutrient intakes to one level of energy intake. The residual 
method involves performing a regression to predict nutrient intakes from total energy 
intake. The residuals (difference between raw nutrient intakes and predicted nutrient 
intakes) can then be added to a constant (the nutrient intake predicated from the mean 
total energy intake) to derive energy-adjusted nutrient intakes. In this data set, nutrient 
intakes are standardized to 2000 kilocalories (Kcal).  
Patients also completed a supplement use questionnaire (Appendix 8.5). From a 
list, they were asked to check any supplements they use with an option to record 
supplements not on the list. They were also asked to record the dose, brand, frequency 
and duration of use. The nutrient composition of each supplement taken (including 
multivitamins) was recorded. If the exact brand was not reported, the most commonly 
used brand was used.  
 
3.4 Blood Collection 
A study nurse collected blood by venipuncture before sanative therapy and at the 
re-exam. 5 mL of blood was collected into a glass red top serum vacutainer tube with no 
additive (BD-Canada, Mississauga, ON). Tubes were placed in a refrigerator (2-8°C) and 
allowed to clot for at least an hour. Blood was centrifuged at room temperature in a table 
top centrifuge (Hettich EBA 270) for 15 minutes at 1,268 x g. Serum was collected in 
200 microliter (µL) and 600 µL aliquots and stored at -80°C.    
	   56	  
3.5 Vitamin D Status  
Frozen baseline serum samples were delivered to Life Labs Medical Laboratory 
Services (St. Catharines, ON). Serum 25-hydroxyvitamin D levels were measured 
according to their standardized medical laboratory procedures using the Liaison 
chemiluminescence system (DiaSorin, Mississauga, ON). The Liaison system is currently 
used in many clinical and research laboratories [174-176].    
 
3.6 Patient Information 
Patient information including age, gender, smoking status (recorded as never, 
former or current), allergies, health conditions and medication use were collected from 
the patient’s medical history form (Appendix 8.6).  
 
3.7 Anthropometry and Physical Activity 
Body dimensions and physical activity were measured, as they may be potential 
confounders. Before sanative therapy and at the re-exam, patients met with a study nurse 
to have their height and weight (Health o Meter Professional) measured without shoes in 
order to calculate their BMI. Patients had their waist circumference (measured at the top 
of the iliac crest) and their hip circumference (measured at the widest part of the hips) 
measured with a non-stretchable measuring tape in order to calculate their waist-to-hip 
ratio. Patients also completed the Godin Leisure-Time Exercise Questionnaire (Appendix 
8.7), a validated tool that measures leisure time exercise behavior [177]. Among BMI, 
waist-to-hip ratio and physical activity, waist-to-hip ratio was found to be the best 
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predictor of periodontal disease outcomes (data not shown) and thus was the only one of 
the three included as a covariate in regression analyses.     
 
3.8 Statistical Analysis  
 The relationship between dietary intakes and probing depth was investigated 
using hierarchical multiple linear regression (MLR). Dietary intakes of vitamin C, EPA 
and DHA and serum 25(OH)D were each used as continuous predictors and re-exam PD 
was used as a continuous outcome.  
 Before investigating the effects of diet, a basic model was created to evaluate 
periodontal healing (Table 3.1). Baseline PD was included in the model because we were 
interested in the response to sanative therapy and therefore needed variation due to 
differences in PD before sanative therapy removed. Large effect size clinical variables 
that might obscure the effects of diet (smoking status, follow-up time and hygienist 
performing sanative therapy) were then included in the model to determine if they would 
need to be controlled for. Baseline PD, current smoking, follow-up time, and hygienist 
performing sanative therapy were all significant predictors of re-exam PD (p < 0.05). In 
order to adjust for these effects, current smokers (n = 19) were excluded from further 
analyses since smoking undoubtedly reduces a patient’s response to sanative therapy [33] 
and because smokers have different nutritional requirements than non-smokers [178]. 
Ideally, stratified analyses would have been performed, however, there was an 
insufficient number of current smokers to do that.  In order to minimize the effect of 
follow-up time, participants who took longer than four months to return for their re-exam 
were excluded (n = 4). This was a reasonable cut-off point as relapse of periodontal 
	   58	  
disease begins within less than half a year [179]. Thus, too late of a re-examination would 
not be an accurate assessment of the initial response to sanative therapy. Finally, as there 
were differences in PD based on which hygienist performed sanative therapy, control for 
hygienist was included in statistical models. All MLR models were therefore adjusted for 
baseline PD, follow-up time and hygienist before looking for associations with diet 
variables. 
 For each dietary predictor, a second MLR model was created, which further 
adjusted for age (years), sex (male or female), waist-to-hip ratio, former smoking (yes or 
no), plaque (% teeth), and dietary supplement use (yes or no) in order to control for 
possible confounders. Although other possible confounders exist such as health 
conditions, medication use and allergies, they were not controlled for because we set a 
limit of ten predictors in our regression models because we had a modest sample size and 
wanted to avoid over-parameterization of the data and loss of power. Values reported are: 
R2 (amount of variance explained by the model), R2Adj (generalizability of the model to 
other populations), ΔR2 (amount of unique variance explained by the predictor of 
interest), B (regression coefficient: change in outcome for each change in unit of the 
predictor) and β (standardized regression coefficient to compare the effect size of 
different predictors). Predictors and outcomes were verified for normality. An outcome 
was considered normally distributed if its skewness was less than 3.29 [180]. Non-normal 
data was transformed into normal scores using Blom’s rank-based normalization formula. 
Models were also verified for homoscedasticity, independence of errors (Durbin-Watson 
> 1 and < 3), the absence of mullticollinearity (tolerance > 0.2 and variance inflation 
factor << 10) and the absence of multivariate outliers using Mahalanobis distance. 
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 Dietary supplement use was investigated using analysis of covariance 
(ANCOVA). Individuals who took various types of supplements (any supplement, 
multivitamin, vitamin C, vitamin D and omega-3) were compared to a control group 
(individuals who did not report taking any supplements). Re-exam PD was used as a 
continuous outcome and baseline PD, follow-up time and hygienist were used as 
covariates in the model. Adjusted means ± stander errors of the mean (SEM) and ηp2 (a 
measure of effect size) are reported. The statistical assumptions of homogeneity of 
variance, univariate normal distribution, independence of covariate and treatment, and 
homogeneity of regression were verified.     
 All statistical procedures were performed using SPSS version 20. Statistical 
significance was defined as p < 0.05. 
   
Table 3.1 Model for predicting re-exam PD  
    B ± SE (mm) β  P value 
Baseline PD (mm)   0.19 ± 0.02 0.65 < 0.001 
Follow-up time (months)   0.03 ±	  0.01 0.17 0.008 
Dental hygienist    
      Hygienist 1 (n = 19) Reference Reference - 
      Hygienist 2 (n = 31) - 0.07 ± 0.03 - 0.16 0.034 
      Hygienist 3 (n = 21)   0.01 ± 0.04   0.02 NS 
      Hygienist 4 (n = 8) - 0.03 ± 0.05 - 0.05 NS 
Smoking status     
      Never (n = 32) Reference Reference - 
      Former (n = 28)   0.03 ± 0.03 0.06 NS 
      Current (n = 19)   0.13 ± 0.04 0.28 < 0.001 
R2 = 0.72, R2Adj = 0.69, p < 0.001 
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Table 3.2 Variables used in each statistical model 
Model 1 Model 2 
Baseline probing depth (mm) Baseline probing depth (mm) 
Hygienist (1,2,3,4) Hygienist (1,2,3,4) 
Follow-up time (days) Follow-up time (days) 
 Age (years) 
 Sex (male or female) 
 Waist-to-hip ratio 
 Former smoker (yes or no) 
 Plaque score (% teeth) 
 Dietary supplement use (yes or no) 
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Chapter Four 
 
RESULTS 
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 In total, 91 patients participated in the study. Of those, 12 did not return their food 
frequency questionnaire and were thus excluded. Current smokers (n = 19) and those who 
took longer than 4 months to return for their re-exam (n = 4) were excluded leaving of 
final sample size of 56. The participant characteristics, clinical outcomes and dietary 
intakes are described in Table 4.1.  
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Table 4.1 Participant characteristics, clinical outcomes and dietary intakes 
Age (years) 59 ± 13 (23 – 90) 
Sex [n (%)]  
      Males  26 (46) 
      Females  30 (54) 
BMI [n (%)]  
      Normal (18.5 – 24.9) 9 (16) 
      Overweight (25.0 – 29.9) 30 (54) 
      Obese (30.0 +) 17 (30) 
Waist-to-hip ratio - Males 0.93 ± 0.06 (0.78 – 1.04) 
Waist-to-hip ratio - Females 0.84 ± 0.06 (0.72 – 0.95) 
Smoking Status [n (%)]  
      Never smoked 30 (54) 
      Former smokers  26 (46) 
Diabetics [n (%)] 5 (9) 
Baseline Clinical Measures  
      No. Teeth  24 ± 4 (12 – 32) 
      Probing depth (mm) 3.96 ± 0.63 (3.07 – 5.80) 
      Sites 4-6 mm (n) 75 ± 33 (7 – 139) 
      Sites > 7 mm (n) 8 ± 12 (0 – 53) 
      Bleeding on probing (%) 47 ± 29 (0 – 100) 
      Plaque score 72 ± 28 (10 – 100) 
Re-Exam Clinical Measures  
      Probing depth (mm) 3.12 ± 0.11 (3.00 – 3.41) 
      Sites 4-6 mm (n) 12 ± 10 (0 – 40) 
      Sites > 7 mm (n) 0 ± 0.5 (0 – 2) 
      Bleeding on probing (%) 4 ± 5 (0 – 23) 
      Plaque score 32 ± 22 (0 – 100) 
Follow-up time (days) 74 ± 15 (50 – 116) 
Nutrient Intakes  
      Total energy (Kcal) 1550 ± 600 (719 – 3158) 
      Dietary vitamin C (mg) 135 ± 57 (37 – 352) 
      Total vitamin C (mg) 318 ± 364 (69 – 2172) 
      Dietary vitamin D (IU) 181 ± 112 (29 – 707) 
      Total vitamin D (IU) 1047 ± 1211 (31 – 6705) 
      Dietary EPA (mg) 39 ± 32 (0 – 172) 
      Total EPA (mg) 95 ± 176 (0 – 944) 
      Dietary DHA (mg) 61 ± 45 (0 – 244) 
      Total DHA (mg) 97 ± 120 (0 – 659) 
25-hydroxyvitamin D (nmol/L) 66 ± 24 (13 – 118) 
Daily dietary supplement use [n (%)]  
      No supplements  19 (34) 
      Any supplement  37 (66) 
      Multivitamin 20 (36) 
      Vitamin C (≥ 500 mg/day) 12 (21) 
      Vitamin D (≥ 1000 IU/day) 22 (39) 
      Fish Oil 
      Omega 3/6/9 
10 (14) 
2 (4) 
Data are expressed as mean ± SD (range) for continuous variables and counts (%) for categorical variables.  
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 The regression analyses by dietary intakes and total intakes (diet + supplements) 
of vitamin C, vitamin D, EPA and DHA, as well as serum 25(OH)D concentrations are 
summarized in Table 4.2. Dietary intakes of nutrients and serum 25(OH)D were 
normally distributed while total intakes were positively skewed and therefore transformed 
into normal scores.  
 
Vitamin C Intake  
 Hierarchical MLR was performed to predict re-exam PD using vitamin C intake 
as a continuous predictor. After controlling for baseline PD, hygienist and follow-up 
time, there was a trend for lower re-exam PD with higher dietary intakes of vitamin C but 
it did not reach statistical significance (ΔR2 = 0.03, β = - 0.18, p = 0.07). The strength of 
the association remained consistent after adjustment for baseline PD, hygienist, follow-up 
time plus potential confounders including age, sex, waist-to-hip ratio, former smoking, 
plaque score, and dietary supplement use (ΔR2 = 0.03, β = - 0.18, p = 0.07). There were 
no significant associations with total (diet + supplement) intake of vitamin C. 
 
Vitamin D Intake and Serum 25(OH)D  
  Hierarchical MLR was performed to predict re-exam PD using vitamin D intake 
as a continuous predictor. After controlling for baseline PD, hygienist and follow-up 
time, there were no significant associations with either dietary or total intake of vitamin D 
and re-exam PD. Similarly after controlling for baseline PD, hygienist, follow-up time 
plus potential confounders including age, sex, waist-to-hip ratio, former smoking, plaque 
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score, and dietary supplement use, there were no significant associations with either 
dietary or total intake of vitamin D and re-exam PD.  
 The average serum 25(OH)D was 66 ± 24 nmol/L and ranged from 13 – 118 
nmol/L. 82% of the population had serum 25(OH)D ≥ 50 nmol/L and 29% had serum 
25(OH)D ≥ 75 nmol/L. Serum 25(OH)D was not significantly associated with dietary 
intake of vitamin D (r = 0.01, p = 0.92) or total (diet + supplemental) intake of vitamin D 
(r = 0.21, p = 0.12). Vitamin D supplement users (dose ≥ 1000 IU/day) had a higher 
serum 25(OH)D compared to non-users (78 ± 24 nmol/L vs. 59 ± 21 nmol/L, t = -3.15, p 
= 0.003). Hierarchical MLR was performed to predict re-exam PD using serum 25(OH)D 
as a continuous predictor. After controlling for baseline PD, hygienist and follow-up 
time, there was no significant associations with 25(OH)D and re-exam PD. Similarly 
after controlling for baseline PD, hygienist, follow-up time plus potential confounders 
including age, sex, waist-to-hip ratio, former smoking, plaque score, and dietary 
supplement use, there was no significant associations with serum 25(OH)D and re-exam 
PD. 
 
EPA and DHA Intake  
 After controlling for baseline PD, hygienist and follow-up time, there were no 
significant associations between re-exam PD and any of dietary EPA, total EPA, dietary 
DHA or total DHA. This remained consistent when the models were adjusted for baseline 
PD, hygienist, follow-up time plus potential confounders including age, sex, waist-to-hip 
ratio, former smoking, plaque score, and dietary supplement use. 
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Table 4.2 Regression of re-exam PD (mm) by intakes of vitamin C, D, EPA and DHA 
 
 R2 R2adj ΔR2 B ± SE (mm) β  P value 
Vitamin C - DIET (100 mg)       
      Model 1 0.62 0.57 0.03 - 0.03 ± 0.02 - 0.18 0.07 
      Model 2 0.64 0.54 0.03 - 0.04 ± 0.02 - 0.18 0.07 
Vitamin C – DIET + SUPP        
      Model 1 0.59 0.54 0.00 - 0.01 ± 0.01 - 0.05 NS 
      Model 2 0.61 0.50 0.00 - 0.01 ± 0.01 - 0.05 NS 
Vitamin D – DIET (100 IU)       
      Model 1 0.59 0.54 0.00   0.00 ± 0.01   0.04 NS 
      Model 2 0.61 0.50 0.00 0.00 ± 0.01   0.03 NS 
Vitamin D – DIET + SUPP        
      Model 1 0.59 0.54 0.00 - 0.01 ± 0.01 - 0.04 NS 
      Model 2 0.61 0.50 0.00 - 0.01 ± 0.02 - 0.09 NS 
Serum 25(OH)D (10 nmol/L)       
      Model 1 0.59 0.54 0.00   0.00 ± 0.01 - 0.04 NS 
      Model 2 0.61 0.50 0.00   0.00 ± 0.01 - 0.03 NS 
EPA – DIET  (1 g)       
      Model 1 0.60 0.55 0.01 - 0.30 ± 0.33 - 0.09 NS 
      Model 2 0.62 0.51 0.01 - 0.36 ± 0.36 - 0.11 NS 
EPA – DIET + SUPP       
      Model 1 0.61 0.56 0.02 - 0.01 ± 0.01 - 0.13 NS 
      Model 2 0.63 0.52 0.02 - 0.06 ±	  0.01  - 0.14 NS 
DHA – DIET  (1 g)       
      Model 1 0.60 0.55 0.01 - 0.20 ± 0.24 - 0.08 NS 
      Model 2 0.62 0.51 0.01 - 0.25 ± 0.26 - 0.10 NS 
DHA – DIET + SUPP       
      Model 1 0.61 0.56 0.02 - 0.02 ± 0.01 - 0.15 NS 
      Model 2 0.63 0.52 0.02 - 0.02 ± 0.01 - 0.16 NS 
 
Model 1: Adjusted for baseline PD, hygienist and follow-up time.  
Model 2: Adjusted for baseline PD, hygienist, follow-up time, age, sex, former smoking, waist-
to-hip ratio, plaque score, and supplement use.  
Regression coefficients are expressed in terms of the unit shown in brackets for each predictor. 
For example, there is a 0.03 ± 0.02 mm reduction in PD for every 100 mg of vitamin C. 
Predictors listed without a unit of measurement are normal scores.   
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Dietary Supplement Use 
 
 Dietary supplement users were compared to non-users using ANCOVA to control 
for baseline PD, hygienist and follow-up time (summarized in Table 4.3). The adjusted 
re-exam PD for non-users (n = 19) was 3.12 ± 0.02 mm and this group comprises the 
control group for all ANCOVA comparisons. The adjusted re-exam PD for those who 
reported taking any kind of dietary supplement (n = 37) was 3.12 ± 0.01 mm. There was 
no significant difference in re-exam PD between supplement users and the control group. 
Multivitamin supplement users (n = 20) had an adjusted re-exam PD of 3.12 ± 0.02, 
which was not significantly different from the control group. Vitamin C supplement users 
(n = 12) had an adjusted re-exam PD of 3.10 ± 0.02 mm but they were not significantly 
different from the control group. Vitamin D supplement users (n = 22) had an adjusted re-
exam PD of 3.11 ± 0.02 mm but they were not significantly different from the control 
group. Omega-3 (fish oil + omega3/6/9) supplement users (n = 12) had an adjusted re-
exam PD of 3.11 ± 0.02 mm but they were not significantly different from the control 
group.  
 
 
Table 4.3 Comparison of re-exam PD (mm) between supplement users and non-users  
 
n PD: Mean ± SE (mm) Comparison to control  ηp2 P value 
Non-users (control) 19 3.12 ± 0.02 - - 
Any Supplement 37 3.12 ± 0.01 0.00 0.73 
Multivitamin 20 3.12 ± 0.02 0.00 0.87 
Vitamin C 12 3.10 ± 0.02 0.03 0.40 
Vitamin D 22 3.11 ± 0.02 0.02 0.45 
Omega-3 10 3.11 ± 0.02 0.00 0.82 
Covariates are baseline PD, hygienist, and follow-up time.  
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Exploratory Analyses 
 Due to the fact that this is the first study to investigate the relationship between 
diet and periodontal outcomes after sanative therapy, we further explored associations 
with variables provided in the nutrition report. Due to the nature of exploring associations 
without a priori hypotheses, we acknowledge the possibility of finding associations by 
chance. Additionally, due to the relatively modest sample size in this study, it would be 
underpowered to detect any associations if a correction (such as Bonferroni) was used for 
multiple comparisons. Therefore, findings from these exploratory analyses are for the 
purpose of guiding future research projects and separate studies with the proper a priori 
hypotheses will be needed to validate any findings. 
 
Polyunsaturated Fatty Acids 
 Since EPA and DHA intakes were relatively low in the study population, we 
decided to investigate possible associations with essential fatty acids, which were 
consumed in higher amounts by the study population. Intakes of LA, ALA and the 
omega-6 to omega-3 ratio were investigated as potential predictors of re-exam PD.    
 
 Hierarchical MLR was performed to predict re-exam PD using either LA, ALA, 
or omega-6/omega-3 intake as a continuous predictor.  
 After controlling for baseline PD, hygienist and follow-up time, there was a 
significant association between higher intakes of dietary LA and lower re-exam PD (ΔR2 
= 0.03, β = - 0.19, p < 0.05). This association remained consistent when the model was 
adjusted for baseline PD, hygienist, follow-up time plus potential confounders including 
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age, sex, waist-to-hip ratio, former smoking, plaque score, and dietary supplement use 
(ΔR2 = 0.04, β = - 0.22, p = 0.04). In the fully adjusted model, LA intake could uniquely 
explain 4% of the variance in re-exam PD and for each 10 grams of LA consumed there 
was a 0.10 ± 0.05 mm reduction in PD.  This association is depicted visually in Figure 
4.1.  
 After controlling for baseline PD, hygienist and follow-up time, there was also a 
significant association between higher dietary intakes of ALA and lower re-exam PD 
(ΔR2 = 0.05, β = - 0.22, p = 0.01).  This association remained consistent when the model 
was adjusted for baseline PD, hygienist, follow-up time plus potential confounders 
including age, sex, waist-to-hip ratio, former smoking, plaque score, and dietary 
supplement use (ΔR2 = 0.06, β = - 0.26, p = 0.009).  In the fully adjusted model, ALA 
intake could uniquely explain 6% of the variance in re-exam PD and for each gram of 
ALA consumed there was a 0.09 ± 0.03 mm reduction in PD. This association is depicted 
visually in Figure 4.2.  
 After controlling for baseline PD, hygienist and follow-up time, there was a 
significant association between a larger total omega-6 to omega-3 ratio and greater re-
exam PD (ΔR2 = 0.03, β = 0.18, p < 0.05). This association remained consistent when the 
model was adjusted for baseline PD, hygienist, follow-up time plus potential confounders 
including age, sex, waist-to-hip ratio, former smoking, plaque score, and dietary 
supplement use (ΔR2 = 0.04, β = 0.21, p = 0.04). In the fully adjusted model, the omega-6 
to omega-3 ratio could uniquely explain 4% of the variance in PD and for each unit 
increase there was a 0.02 ± 0.01 mm increase in PD. This association is depicted visually 
in Figure 4.3.  
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Table 4.4 Summary of significant associations between PD and essential fatty acid intake 
 
 R2 R2adj ΔR2 B ± SE (mm) β  P value 
LA – DIET  (10 g)       
      Model 1 0.62 0.58 0.03 - 0.08 ± 0.04 - 0.19 0.05 
      Model 2 0.65 0.55 0.04 - 0.10 ± 0.05 - 0.22 0.04 
ALA – DIET  (1 g)       
      Model 1 0.64 0.60 0.05 - 0.08 ± 0.03 - 0.23 0.01 
      Model 2 0.67 0.58 0.06 - 0.09 ± 0.03 - 0.26 0.009 
Total Dietary Omega-6:Omega-3       
      Model 1 0.62 0.56 0.03   0.02 ± 0.01   0.18 0.05 
      Model 2 0.65 0.55 0.04   0.02 ± 0.01   0.21 0.04 
 
Model 1: Adjusted for baseline PD, hygienist and follow-up time 
Model 2: Adjusted for baseline PD, hygienist, follow-up time, age, sex, former smoking, waist-
 to-hip ratio, plaque score, and supplement use 
Regression coefficients are expressed in terms of the unit shown in brackets for each predictor. 
 For example, there is a 0.10 ± 0.05 mm reduction in PD for 10 g of LA.  
 
 
Figure 4.1 Relationship between LA intake and re-exam PD (adjusted for baseline PD, 
hygienist and follow-up time), R2 = 0.03, p = 0.04 
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Figure 4.2 Relationship between ALA intake and re-exam PD (adjusted for baseline PD, 
hygienist and follow-up time), R2 = 0.05, p = 0.01 
 
 
Figure 4.3 Relationship between the omega-6 to omega-3 ratio and re-exam PD (adjusted 
for baseline PD, hygienist and follow-up time), R2 = 0.03, p = 0.04 
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Fruit, Vegetable, Dairy and Milk Intake  
 A second approach to the exploratory analyses was to investigate potential 
relationships with specific food groups.  Because of the relationship between dietary 
intakes of vitamin C and periodontal disease, food sources of vitamin C including fruits 
and vegetables were investigated as potential predictors of periodontal healing. Similarly, 
because of the relationship between vitamin D and periodontal disease, foods that contain 
significant amounts of vitamin D were investigated. Overall dairy intakes as well as milk 
intake (which is the only dairy food that is actually fortified with vitamin D) were 
investigated as potential predictors of periodontal healing.    
 Hierarchical MLR was performed to predict re-exam PD using either fruit, 
vegetable, dairy or milk intake as a continuous predictor. After adjusting for baseline PD, 
hygienist and follow-up time, neither fruit, nor dairy, nor milk intakes were significant 
predictors of re-exam PD. These results remained consistent when the models were 
further adjusted for potential confounders including age, sex, waist-to-hip ratio, former 
smoking, plaque score, and dietary supplement use.  
 After adjusting for baseline PD, hygienist and follow-up time, it was found that 
higher intakes of total vegetables were associated with lower re-exam PD (ΔR2 = 0.05, β 
= - 0.23, p = 0.02). This association remained consistent when the model was adjusted for 
baseline PD, hygienist, follow-up time plus potential confounders including age, sex, 
waist-to-hip ratio, former smoking, plaque score, and dietary supplement use (ΔR2 = 0.06, 
β = - 0.26, p = 0.01). In the fully adjusted model, total vegetable intake uniquely 
explained 6% of the variance in PD and there was a 0.02 ± 0.01 mm reduction in PD for 
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each daily serving (1/2 cup/125 mL) of vegetables consumed. This association is depicted 
visually in Figure 4.4.  
 To further explore this association we analyzed by vegetable subgroup. The 
subgroups are based on the 2005 Dietary Guidelines for Americans. These groups were 
created to ensure adequate intake of all vitamins and minerals as the nutrient composition 
varies between subgroups [181]. American guidelines were used (as opposed to Canadian 
ones) because the company that processes the Block FFQ is American-based and only 
provides dietary assessments based on American guidelines. However, Canada’s Food 
Guide categorizes vegetables into similar groups as they recommend individuals to 
consume dark leafy green and orange vegetables every day.   The subgroups tested were: 
deep yellow orange vegetables (carrots, sweet potatoes, winter squash, and pumpkin), 
dark green leafy vegetables (broccoli, spinach, romaine, collard, turnip, and mustard 
greens), potatoes (white potatoes), starchy vegetables (corn and green peas), tomatoes, 
legumes (pinto beans, kidney beans, lentils, chickpeas, tofu) and other vegetables (in the 
Block FFQ: squash, cauliflower, okra, cooked peppers). After adjusting for baseline PD, 
hygienist and follow-up time, the subgroups that were significantly associated with re-
exam PD (in order of decreasing effect size) were other vegetables (ΔR2 = 0.08, β = -
0.28, p = 0.002), deep yellow orange vegetables (ΔR2 = 0.05, β = - 0.24, p = 0.01) and 
legumes (ΔR2 = 0.04, β = -0.19, p = 0.04). These associations remained consistent when 
the models were adjusted for baseline PD, hygienist, follow-up time plus potential 
confounders including age, sex, waist-to-hip ratio, former smoking, plaque score, and 
dietary supplement use. Associations for deep yellow orange vegetable, legume and other 
vegetable intake are depicted visually in Figures 4.5, 4.6 and 4.7 respectively. 
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 In order to determine possible nutrient and/or bioactive food component 
associations we further analyzed associations with nutrients and bioactives that are 
relatively abundant in vegetables. We tested associations with vitamin A, α-carotene, β-
carotene, β-cryptoxanthin, lutein, lycopene, quercetin, α-tocopherol, vitamin K, and 
potassium. After adjustment for baseline PD, hygienist and follow-up time, β-carotene 
(ΔR2 = 0.05, β = -0.24, p = 0.01) and β-cryptoxanthin (ΔR2 = 0.04, β = -0.22, p = 0.02) 
were significantly associated with re-exam PD. These associations remained consistent 
when the models were adjusted for baseline PD, hygienist, follow-up time plus potential 
confounders including age, sex, waist-to-hip ratio, former smoking, plaque score, and 
dietary supplement use. Associations for β-carotene and β-cryptoxanthin are depicted 
visually in Figures 4.8 and 4.9 respectively. Statistics regarding vegetable subgroups and 
bioactives that were significant predictors of re-exam PD are summarized in Table 4.5.  
 For the exploratory analyses, a summary of intakes and their respective effects are 
summarized in Table 4.6. 
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Table 4.5 Summary of significant associations between PD and vegetable intake 
 
 
 R2 R2adj ΔR2 B ± SE (mm) β  P value 
Total Vegetables (1 serv./125mL)       
      Model 1 0.64 0.59 0.05 - 0.02 ± 0.01 - 0.23 0.02 
      Model 2 0.67 0.57 0.06 - 0.02 ± 0.01 - 0.26 0.01 
Yellow Orange (1 cup/250 mL)       
      Model 1 0.64 0.60 0.05 - 0.14 ± 0.05 - 0.24 0.01 
      Model 2 0.67 0.58 0.06 - 0.16 ± 0.06 - 0.28 0.006 
Legumes (1 cup/250 mL)       
      Model 1 0.63 0.58 0.04 - 0.71 ± 0.33 - 0.19 0.04 
      Model 2 0.66 0.56 0.05 - 0.89 ± 0.36 - 0.24 0.02 
Other Vegetables (1 cup/250 mL)       
      Model 1 0.67 0.63 0.08 - 0.09 ± 0.03 - 0.28 0.002 
      Model 2 0.69 0.61 0.08 - 0.10 ± 0.03 - 0.30 0.002 
β-Carotene (1000 µg)       
      Model 1 0.64 0.60 0.05 - 0.01 ± 0.01 - 0.24 0.01 
      Model 2 0.67 0.58 0.06 - 0.01 ± 0.01 - 0.28 0.006 
β-Cryptoxanthin (0.1 mg)       
      Model 1 0.63 0.59 0.04 - 0.02 ± 0.01 - 0.22 0.02 
      Model 2 0.65 0.55 0.04 - 0.02 ± 0.01 - 0.22 0.03 
 
Model 1: Adjusted for baseline PD, hygienist and follow-up time 
Model 2: Adjusted for baseline PD, hygienist, follow-up time, age, sex, former smoking, waist-
 to-hip ratio, plaque score, and supplement use 
Regression coefficients are expressed in terms of the unit shown in brackets for each predictor. 
 For example, there is a 0.02 ± 0.01 mm reduction in PD for 1 serving of vegetables.  
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Figure 4.4 Relationship between total vegetable intake and re-exam PD (adjusted for 
baseline PD, hygienist and follow-up time), R2 = 0.05, p = 0.02. One serving is ½ cup or 
125 mL. 
 
 
Figure 4.5 Relationship between deep yellow orange vegetable intake and re-exam PD 
(adjusted for baseline PD, hygienist and follow-up time), R2 = 0.05, p = 0.01 
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Figure 4.6 Relationship between legume intake and re-exam PD (adjusted for baseline 
PD, hygienist and follow-up time), R2 = 0.04, p = 0.04 
 
 
 
Figure 4.7 Relationship between other vegetable intake and re-exam PD (adjusted for 
baseline PD, hygienist and follow-up time), R2 = 0.08, p = 0.002 
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Figure 4.8 Relationship between β-carotene intake and re-exam PD (adjusted for 
baseline PD, hygienist and follow-up time), R2 = 0.05, p = 0.01 
 
 
 
Figure 4.9 Relationship between β-cryptoxanthin intake and re-exam PD (adjusted for 
baseline PD, hygienist and follow-up time), R2 = 0.04, p = 0.02 
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Table 4.6 Summary of dietary intakes and their respective effects on mean PD after 
sanative therapy 
Food/Nutrient/Bioactive 
Daily Intakes of 
the population  
Mean ± SD 
(range) 
Effect 
Linoleic Acid (g) 14.4 ± 2.4 
(7.8 – 20.1) 
0.10 ± 0.05 mm 
reduction in PD for 
every 10 g 
α-Linolenic Acid (g) 1.6 ± 0.03 
(0.9 – 2.6) 
0.09 ± 0.03 mm 
reduction in PD for ever 
1 g 
Omega-6 to Omega-3 Ratio 8.6 ± 2.2 
(6.8 – 12.6) 
0.02 ± 0.01 mm 
increase in PD for ever 
unit 
Total Vegetables  
(Serving = ½ cup or 125 mL) 3.8 ± 1.7 (1.0 – 9.2) 0.02 ± 0.01 mm reduction in PD for every serving 
Deep Yellow Orange Vegetables  
(1 cup or 250 mL) 0.22 ±	  0.19	  (0.03	  –	  1.12) 0.16 ± 0.06 mm reduction in PD for every cup 
Legumes (1 cup or 250 mL) 0.06 ± 0.03 
(0.01 – 0.15) 
0.89 ± 0.36 mm 
reduction in PD for 
every cup 
Other Vegetables (1 cup or 250 mL) 0.72 ± 0.33 
(0.08 – 1.8) 
0.10 ± 0.03 mm 
reduction in PD for 
every cup 
β-Carotene (mg) 6.2 ± 3.5 
(1.5 – 18.0) 
0.01 ± 0.01 mm 
reduction in PD for 
every mg 
β-Cryptoxanthin (µg) 219 ±	  151	  (0	  –	  708) 0.02 ± 0.01 mm reduction in PD for every 100 µg 
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Chapter Five 
 
DISCUSSION AND CONCLUSIONS 
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5.1 Discussion  
 This study was the first to investigate the relationship between diet and 
periodontal healing following sanative therapy. Although we had hypothesized that 
higher intake of specific nutrients such as vitamin C, vitamin D, EPA and DHA, either 
through diet or supplement use, would be associated with lower PDs, these findings were 
not observed. Similarly, we had hypothesized that higher serum 25(OH)D would be 
associated with lower PDs, but this finding was not observed. However, diets rich in 
essential fatty acids (linoleic acid and α-linolenic acid) and rich in vegetables were 
associated with a better response to sanative therapy, suggesting that a diet incorporating 
these elements may be an effective strategy to optimize healing after periodontal 
treatment.  
 Our study population was fairly similar to the general Canadian population in 
terms of health behaviours including body weight and smoking. From 2009 to 2011, 
Statistics Canada reports that for males 40 to 79, 42 – 45 % of the population is 
overweight and 31 – 36 % of the population is obese [182]. Similarly for females age 40 
– 79, 30 – 35 % of the population is overweight and 28 – 32 % of the population is obese. 
These proportions are similar to those observed in our study population, which had 
slightly more overweight individuals (54 %) but a similar proportion of obese individuals 
(30 %). In terms of smoking, 20.3 % of Canadians over 12 years of age were current 
smokers in 2012 [183]. Of those that do not currently smoke in Canada, about half are 
former smokers. The proportion of smokers in the study population was slightly higher 
with 26 % of patients being current smokers with a comparable proportion of former 
smokers (50% of non-smokers).   
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 In addition to associations with nutrition, we observed other significant predictors 
of periodontal healing including the number of days between treatment and follow-up, 
and which hygienist the patient saw. The relationship between follow-up time and mean 
PD is consistent with the literature. After the initial healing and reduction in PD there is a 
natural tendency for some relapse to occur within six months of treatment [179]. To 
compensate in this study, patients at the extreme end (longer than 4 months for follow-
up) were removed and follow-up time was then controlled for statistically. Also in this 
study, patients who saw hygienist number 2 had a significantly lower mean probing depth 
compared to the other hygienists. This could have resulted either due to greater efficacy 
in performing sanative therapy or due to differences in technique when measuring follow-
up PD. Differences in measurement of PD is a probable explanation as measuring PD can 
be quite variable and depends on factors such as probing force and probing position [3]. 
Although we attempted to minimize any systematic differences in measurement 
technique by calibrating the hygienists prior to the study, difference still occurred. Since 
it was not feasible to discard patients seen by hygienists number 2 due to sample size, the 
best compromise was to control statistically for differences that might have occurred due 
to which hygienist the patient saw.     
 
Vitamin C  
 Vitamin C was hypothesized to improve the response to sanative therapy by 
acting as an anti-oxidant and promoting collagen synthesis. Although this study did not 
find a significant association between vitamin C intake and PD, one explanation for this 
result could be an inadequate sample size. There was an almost significant trend (p = 
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0.07) for reduced PD with higher dietary intakes of vitamin C and therefore we still 
consider dietary vitamin C to be potentially associated with periodontal healing. The 
current analysis has a power of 0.38. To detect this association with α = 0.05 and power = 0.80 would require a sample size of 189. Eighty percent power is, however, quite high, 
and a power of 0.50 requiring 84 participants would likely detect a significant 
association. Significant associations may also have been more readily detected using a 
different method of measuring vitamin C intake or a direct measure of vitamin C status. 
Block FFQ estimates of vitamin C intake have been compared to both intake estimates 
from multiple diet records (two four-day records) [169] and plasma vitamin C [184] 
resulting in modest correlations of r = 0.57 and r = 0.43 respectively. There is not yet an 
agreement on which is the best method as each has its advantages and disadvantages.  For 
example, a FFQ measures usual intakes and therefore might not be as precise as a diet 
record. A diet record may be more precise for a given time period but may not reflect 
usual intakes. Similarly, plasma vitamin C is a good indicator of present vitamin C status 
but may not reflect past or usual vitamin C status. Ideally both a measure of vitamin C 
intake and status would have been useful and thus remains a limitation of this study.  
 As this is the first study to look at vitamin C intake in relation to sanative therapy, 
there are no other studies with which to directly compare these results.  Several 
association studies in the general population have found that higher dietary intakes of 
vitamin C reduce an individual’s risk for periodontitis [100, 107-109]. Dietary intakes 
between 100 and 179 mg/day were found to be the most protective in the United States 
NHANES study. Comparatively, those in the highest tertile of vitamin C intake in our 
study were consuming 151 to 352 mg/day. This might suggest that even higher vitamin C 
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intakes are required to promote periodontal healing compared to only providing 
protection from periodontitis. Intake levels that possibly promote periodontal healing 
appear higher than recommendation for healthy individuals (RDA 90 mg/d for males and 
75 mg/day for females).  
 Interestingly, there did not appear to be a benefit to sanative therapy with use of 
vitamin C supplements (minimum dose of 500 mg/day).  Although vitamin C supplement 
users tended to have lower probing depths, the difference was very small (0.02 mm) and 
thus not significantly different. This effect size is so small that it would require 318 
supplement users for 80% power and 156 supplement users for 50% power. It is therefore 
reasonable to conclude that vitamin C supplements are not likely to improve outcomes 
after sanative therapy. This finding agrees with the study by Abou-Sulaiman [115], who 
supplemented patients undergoing sanative therapy with 2000 mg of vitamin C a day and 
found no differences in clinical outcomes. Although these findings are in agreement, 
there should be caution in drawing any definite conclusion as the Abou –Sulaiman study 
had significant limitations (mostly failure to control for baseline status).     
 In terms of potential mechanisms with dietary vitamin C intake, we hypothesized 
that vitamin C would optimize periodontal healing by first scavenging reactive oxygen 
species thereby reducing periodontal destruction and inflammation, which would allow 
healing to take place, and secondly by acting as an essential cofactor to optimize collagen 
synthesis and aid in periodontal regeneration (Figure 1.3). However, the fact that there 
was no benefit with vitamin C supplements suggests that there are aspects not yet 
identified in this proposed mechanism, as high doses of vitamin C alone do not seem to 
produce an effect. Since fruits and vegetables are a rich source of vitamin C, associations 
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with vitamin C intake might simply be reflecting associations with fruit and vegetable 
intake, which is supported by the results of this study. It may therefore be erroneous to try 
and attribute the positive effects of a healthy fruit and vegetable rich diet to a single 
nutrient, a concept that will be further discussed shortly.  
 
Vitamin D 
 We had hypothesized that higher serum vitamin D levels would optimize healing 
after sanative therapy by boosting the innate immune response to clear pathogenic 
bacteria and by acting as an anti-inflammatory agent to help resolve inflammation in 
order for healing to proceed (Figure 1.3). However, we did not find an association 
between serum vitamin D levels and reduced probing depth. Similarly, there was no 
association between vitamin D intake or vitamin D supplement use and reduced probing 
depth. At the time the present study was planned, there was one study by Bashutski et al. 
[134] who found that patients undergoing open flap debridement had greater reductions 
in probing depth when their serum 25(OH)D was greater than 50 nmol/L. Thus, this study 
was used somewhat as a basis for the present study. However, we had suspected 
problems with their findings as 4/7 (57%) of their control group were smokers and only 
2/13 (15%) of the high vitamin D group were smokers. Additionally, because their 
sample size was so small, the findings would have been highly susceptible to sampling 
error. Our data would suggest that the differences in periodontal healing they claim to be 
due to vitamin D status may be due to effects of smoking, as smoking may hinder the 
response of a patient to sanative therapy. 
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 In retrospect, the lack of association between vitamin D status and periodontal 
healing is not that surprising as we found no literature on the effects of vitamin D and 
soft tissue healing. There is some evidence demonstrating a positive effect of vitamin D 
on fracture healing in animal studies [185], however, that is likely due to the osteogenic 
effects of vitamin D. To date though, there does not appear to be any such studies with 
soft tissue healing. Although the negative effects of inflammation on cutaneous wound 
healing have been well documented [186], that link has not been extended to include any 
modulatory effect of vitamin D.  
 Although we did not find a relationship between vitamin D and periodontal 
outcomes after sanative therapy, that does not exclude the possibility of a role for vitamin 
D in the periodontal clinic. As the epidemiological evidence suggests, high serum vitamin 
D levels (> 85 nmol/L) may serve a protective role in periodontal health [101, 130]. This 
is also supported by cell culture studies showing effects of vitamin D on the innate 
immune response to oral pathogens [137]. Vitamin D may therefore be useful in 
periodontal maintenance patients. In our sample, only 11/56 (20%) of the population had 
serum 25(OH)D > 85 nmol/L with a small number (18%) still below 50 nmol/L. This 
suggests that there is room for improving the vitamin D status of our patient population. 
To achieve levels comparable to the epidemiological studies would likely require vitamin 
D supplementation as patients taking at least 1000 IU of vitamin D per day had a mean 
serum 25(OH)D of 78 ± 24 nmol/L compared to 59 ± 21 nmol/L in patients not taking 
vitamin D supplements. Ensuring adequate vitamin D levels might help patients who 
have undergone sanative therapy maintain their periodontal health and prevent relapses of 
the disease. Indeed, Miley et al. [133] tested this idea by comparing periodontal health of 
	   87	  
patients who were in a maintenance program (frequency of visits not reported but at least 
6 months since initial sanative therapy) and were or were not taking vitamin D 
supplements. They found that vitamin D supplement users had lower probing depths and 
lower levels of attachment loss. So although our study did not see a benefit to sanative 
therapy with higher vitamin D levels, the possible long-term role of vitamin D in patients 
undergoing periodontal treatment warrants further investigation. 
 
EPA and DHA 
 We had hypothesized that higher intakes of EPA and DHA would be associated 
with reduced PD due to their ability to help resolve inflammation (Figure 1.3), however, 
neither EPA nor DHA intakes were associated with re-exam PD. The lack of association 
could be due to a number of potential reasons. Firstly, intakes of EPA and DHA may 
have been too low to exert a measurable effect. In this study the average intake of EPA 
was 39 ± 32 mg/day (range 0 – 172) and the average intake of DHA was 61 ± 45 mg/day 
(range 0 - 244). In the study by El-Sharkawy et al. [159] patients undergoing sanative 
therapy had greater PD reduction and attachment gain with 900 mg of fish oil per day  + 
low dose aspirin. This intervention would have provided roughly an additional 120 mg of 
EPA and 160 mg of DHA per day making intakes higher than those in our study. 
Similarly, in the pilot study by Rosenstein et al. [158], a trend for reduced PD was seen in 
patients taking 3000 mg/day of EPA, which was significantly higher than reported in our 
study. Even some of the dietary observational studies have reported considerably higher 
intakes of EPA and DHA than seen in this seen in this study. For example, in the study by 
Iwasaki et al. [156], those in the highest tertile of DHA intake had reduced risk for 
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periodontal disease, however, the average intake of DHA for that whole population was 
1086 ± 731 mg/day for males and 656 ± 327 mg/day for females. Thus, it is quite 
possible that participants in our study were simply not consuming high enough amounts 
of EPA and DHA to modulate periodontal therapy. It is possible that lower intakes, such 
as the ones seen in this study, might positively affect the response to sanative therapy; 
however, the effect size would be quite small. For example, to detect an association with 
EPA would require 224 participants for 50% power and 509 participants for 80% power 
and to detect an association with DHA intake would require 271 participants for 50% 
power and 617 participants for 80% power. It is also possible that the associations in our 
study were attenuated by inaccuracies in the quantification of EPA and DHA intake. 
Most dietary EPA and DHA come from fish intake and therefore the majority of their 
estimated intakes come from only three questions in the Block FFQ (Appendix 8.4, page 
4). Also, novel foods containing relatively high concentrations of DHA are now more 
common and this is not captured in the Block 2005 FFQ. The novel foods, including eggs 
(15 mg DHA/egg), milk (10 mg DHA/cup) and margarine (30 mg DHA/teaspoon), would 
considerably increase intake among individuals who would otherwise have low DHA 
intakes [187]. Indeed some researchers have shown that food frequency questionnaires 
that are targeted toward long chain fatty acids more accurately quantify EPA and DHA 
intake compared to general FFQs (this may be the case for other nutrients but that has not 
been directly studied). Meyer et al. [188] compared the validity of the Anti-Cancer 
Council of Victoria Dietary Questionnaire (ACCDQ), a tool similar to the Block FFQ in 
Australia, against a PUFA-targeted FFQ. Using erythrocyte EPA as a reference, the 
validity of the PUFA FFQ was 0.92 compared to only 0.19 in the ACCDQ. Similarly, 
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using plasma as a reference, the validity of the PUFA FFQ was 0.96 compared to 0.49 in 
the ACCDQ. Thus it is quite possible that in our study, which used a general FFQ, EPA 
and DHA were not quantified accurately enough. Therefore, the relationship between 
EPA and DHA intake and periodontal therapy may still warrant further investigation, but 
may require different tools for measuring nutrient intakes.  
 In addition to the lack of association with EPA and DHA dietary intakes, we also 
did not find an association between omega-3 supplement use and PD reduction. Although 
this may suggest no effect of omega-3 supplements, these results should not be taken 
very definitively. There were very few omega-3 supplement users in the population. Only 
10 patients reported using fish oil supplements while only 2 reported using omega 3/6/9 
supplements. There was a large amount of heterogeneity in the composition and dosages 
of the supplements. For example, omega-3 supplements provided anywhere from 25 to 
600 mg of DHA. Thus, it is difficult to consider the omega-3 supplement user group as a 
homogenous group such as one you would see in a clinical trial. So although we did not 
find evidence for a benefit with omega-3 supplementation, this study is not equipped to 
show that there is no effect. Since omega-3 supplement use was uncommon in the study 
population, a clinical trial with omega-3 supplements would be a faster approach to 
determine if they optimize periodontal healing after sanative therapy.  
 
Linoleic Acid, α-Linolenic acid and omega-6 to omega-3 ratio 
 Originally, we had not hypothesized associations between LA or ALA intake and 
periodontal healing because the anti-inflammatory mechanisms of PUFAs are thought to 
predominately occur through the action of the longer chain fatty acids EPA and DHA. 
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Nonetheless, there were significant associations between PD and LA or ALA. Individuals 
consuming more LA and ALA had greater reductions in PD compared to those 
consuming less. In this population, the mean energy adjusted LA intake was 14.4 ± 2.4 
g/day and the mean energy adjusted ALA intake was 1.6 ± 0.3 g/day. The highest tertile 
of intake, and thus the level most associated with optimized periodontal healing, ranged 
from 15 - 20 g/day for LA and 1.7 – 2.6 g/day for ALA.  Compared to the RDAs [LA: 
14-17 g/d (males), 11-12 g/d (females), ALA 1.6 g/d (males) and 1.1 g/d (females)], these 
levels are slightly exceeding recommended intakes although it is difficult to compare 
directly due to energy adjustment.  
 This is the first study to report a link between LA, ALA and periodontal 
outcomes. Interestingly, the epidemiological evidence from NHANES showed 
associations between periodontal disease and DHA intake but not with ALA intake [102]. 
That finding seems intuitive as omega-3 PUFAs are known to modulate inflammation 
through EPA, DHA, and resolvins, with very low conversion of ALA into EPA and DHA 
(about 10%) [189]. There then exists a mystery of why, in this study, ALA intake was 
associated with periodontal healing while EPA and DHA, the more active metabolites, 
were not.  One possible explanation is that the lack of EPA and DHA association was due 
to relatively low amounts in the diet, as was previously discussed. Perhaps then high 
enough levels of ALA might be able to generate sufficient quantities of endogenous EPA 
and DHA despite low conversion rates. Goyens et al. [189] report conversion rates in 
humans between 6 and 10%. For example then, if only 10% of 1.6 g of ALA was 
converted to EPA, that would represent 160 mg of EPA, which is still higher than average 
EPA intakes in this population (39 ± 32 mg). Research into other chronic diseases is 
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revealing differential effects of ALA compared to EPA and DHA. Similarly to our study, 
Farina et al. [190] found associations between reduced risk of hip fracture in older adults 
and higher intakes of ALA but not but not with higher intakes of EPA, DHA or fish. 
They explained this finding to be the result of very low intakes of dietary EPA and DHA 
in that population. Another possible explanation is that ALA acts through pathways that 
are not dependent on conversion to EPA and DHA. Very recent research using computer 
modeling suggests that ALA might have anti-inflammatory activity itself by inhibition of 
COX-2, although more work is needed to verify this claim [191].  
 Nonetheless, evidence from this study suggests that ALA rich diets may be 
beneficial for periodontal healing after sanative therapy. Dietary interventions could 
increase ALA intake with foods such as flaxseed (2.4 g/tsp.), canola oil (0.42 g/tsp.), 
flaxseed oil (2.58 g/tsp.), almonds (0.15 g/0.25 cup) and soybeans (0.76 g/0.75 cup). 
These foods could be incorporated into a diet modification plan in order to test this 
hypothesis. Many clinical studies have reported benefits with flaxseed intervention. In 
hypertensive patients, flaxseed intervention has provided clinically significant reductions 
in systolic (- 10 mm Hg) and diastolic (- 7 mm Hg) blood pressure [192]. Furthermore, 
circulating levels of ALA correlated significantly with both systolic and diastolic blood 
pressure. In overweight and obese individuals with pre-diabetes, daily flaxseed 
consumption has been shown to decrease fasting glucose and insulin levels while 
improving insulin sensitivity [193]. Lastly, one study showed that daily flaxseed oil 
consumption for 4 months lowered inflammation (measured as C-reactive protein levels) 
in chronic hemodialysis patients [194]. Although flaxseed is rich in other biologically 
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active compounds such as lignans and fibre, the high content of ALA in flaxseed likely 
plays an important role in mediating these effects.  
 Another surprising finding was that higher LA intake was associated with better 
healing after sanative therapy. LA has received a considerable amount of negative 
attention due to suspected conversion of LA into AA and subsequent conversion into pro-
inflammatory eicosanoids [150]. However, in recent years, this hypothesis has not been 
substantiated. Fifteen randomized, placebo controlled intervention studies with LA in 
healthy adults found no change in multiple markers of inflammation such as C-reactive 
protein, fibrinogen, plasminogen activator inhibitor type 1, cytokines, soluble vascular 
adhesion molecules, or TNF-α [195]. Similarly, 36 intervention studies have found no 
changes in serum, plasma or erythrocyte AA concentrations with either decreased or 
increased LA intake [196]. Thus, there is no evidence to support a link between increased 
LA intake and inflammation in humans. LA intake has been of particular interest in the 
cardiovascular disease literature. Higher LA intakes have been associated with reduced 
risk for coronary heart disease in several large prospective cohort studies such as the 
Health Professionals Follow-up Study [197], the Kupio Heart Study [198] and the 
Nurses’ Health Study [199].  In studies with vascular endothelial cells, omega-6 PUFA 
had anti-inflammatory properties, suppressing the production of adhesion molecules, 
chemokines, and interleukins, although not as strongly as omega-3 PUFA [200]. With 
this evidence in mind, the American Heart Association maintains that higher LA intake 
reduces risk for cardiovascular diseases [201]. Similarly, higher intakes of LA may be 
beneficial for periodontal healing by similar mechanisms. Higher intakes of LA are likely 
	   93	  
not resulting in higher levels of pro-inflammatory eicosanoids and may actually have an 
anti-inflammatory effect.  
 Another finding that adds complexity to the fatty acid story is that, despite 
beneficial associations with both higher ALA and LA intakes, a higher ratio of total 
omega-6 to omega-3 was associated with a less favorable reduction in PD. The 
association between the omega-6 to omega-3 ratio and periodontitis has been reported by 
Iwasaki et al. [157]. They found that a higher ratio was associated with a greater risk for 
the development of periodontal disease. Their lowest tertile of n-6:n-3, and thus the most 
protective level, ranged from 1.9 to 3.4. In our study, the lowest tertile ranged from 6.8 to 
8.2. This range is higher than the Iwasaki study but still lower than ratios obtained by 
following current recommendations in Canada, which suggest an LA:ALA ratio of ~ 
10:1. The traditional explanation for this effect is that a lower omega-6 to omega-3 ratio 
would result in a shift from the production inflammatory omega-6 derived eicosanoids to 
the production of the less inflammatory omega-3 derived eicosanoids as well as more 
available substrate for the formation of resolvin molecules (Figure 1.6). However, based 
on recent evidence surrounding LA intake, this hypothesized mechanism may not be 
accurate. The component of this ratio contributing to inflammation may actually be lower 
intake of omega-3 PUFAs and not higher intake of omega-6 PUFAs. Support for this idea 
is found in intervention studies that change either omega-6 or omega-3 PUFA intake 
while holding the other one constant. Hwang et al. [202] showed that at constant fish oil 
intake, increasing LA had no effect on TXB2 or fibrinogen concentrations while 
conversely, increasing fish oil intake at constant LA intake decreased TXB2 and 
fibrinogen concentrations. Similarly, increasing omega-6 PUFA at constant omega-3 
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intake [203] and constant ALA intake [204] has not resulted in changes in C-reactive 
protein concentrations. Thus, the optimal way to decrease inflammation might be to 
maintain both higher omega-6 PUFA and omega-3 PUFA intake while taking particular 
attention to ensure sufficient omega-3 PUFA intake. Dietary modification that ensures 
adequate omega-6 and omega-3 PUFA may therefore be useful in optimizing sanative 
therapy.  
 
Vegetable Intake 
 The relationship between vegetable intake and periodontal healing following 
sanative therapy is a relatively novel one. We showed that greater vegetable intake was 
associated with a greater reduction in probing depth. Intakes of vegetables in the range of 
4 to 8 servings (1 serving = 1/2 cup or 125 mL) per day for a 2000 kcal diet (highest 
tertile) were the most beneficial. Canada’s Food Guide recommends 7-8 servings of fruits 
and vegetables per day for females 19-50 and 7 servings per day for females over 50. 
Likewise, 8-10 servings per day are recommended for men 19-50 and 7 servings per day 
for men over 50 [165]. Assuming sufficient intakes of fruit, these individuals were 
therefore meeting and possibly exceeding current recommendations for fruit and 
vegetable intake. Furthermore, we were able to show that the associations with vegetable 
intake were stronger for particular types of vegetables, namely yellow/orange vegetables 
(carrots, sweet potatoes, winter squash, and pumpkin), legumes (pinto beans, kidney 
beans, lentils, chickpeas, tofu) and other vegetables. The “other vegetable” group is not 
well defined but according to the foods surveyed in the Block 2005 FFQ, they include 
cauliflower, okra and peppers.  
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 Chapple et al. have documented the benefits of vegetable intake on periodontal 
outcomes in a recent study [205]. They supplemented patients undergoing sanative 
therapy with fruit and vegetable capsules made from blended fruit and vegetable pulp and 
juice powder concentrate. Those receiving the fruit and vegetable intervention had greater 
reductions in PD two months after treatment thus showing that compounds found in fruits 
and vegetables have the capability of optimizing healing after sanative therapy. Clinical 
trials with fruits and vegetables have also effectively modulated inflammation under 
different conditions. For example, 8 servings a day of carotenoid-rich fruits and 
vegetables for 4 weeks has been shown to reduce systemic inflammation (measured as c-
reactive protein levels) in healthy non-smoking men [206]. Similarly, a flavonoid-rich 
fruit and vegetable intervention (6 servings per day) in men at risk for cardiovascular 
disease has been shown to decrease C-reactive protein levels and improve markers of 
endothelial function [207]. Although, fruit and vegetable intervention studies are 
currently sparse, more and more trials are under way to determine if fruit and vegetable 
intake modulates disease activity in a number of pathologies, and periodontal disease 
should be no exception.  
 Vegetable intake may be optimizing periodontal healing through the action of 
many bioactive compounds. Firstly, vegetables are a rich source of antioxidants. Similar 
to vitamin C, other dietary antioxidants are able to accept unpaired reactive electrons 
becoming oxidized in the process by forming a molecule that is more stable than the 
original oxidizing molecule. The decrease in oxidative stress would help resolve 
inflammation and allow healing to proceed. The role for dietary antioxidants from 
vegetables is supported by our data, as β-carotene and β-cryptoxanthin intake were 
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associated with better periodontal healing after sanative therapy. β-Carotene and β-
cryptoxanthin are both carotenoids with antioxidant activity [208]. Iwasaki et al. have 
previously reported an association between dietary β-carotene and periodontal disease 
progression in individuals over 70 years of age [109]. Similarly, the associations with 
various vegetable subgroups might also suggest antioxidant and inflammatory activity 
from bioactives in vegetables. Since orange and yellow vegetable intake was associated 
with improved periodontal healing, these vegetables were likely the source of many of 
the antioxidant compounds such as β-carotene and β-cryptoxanthin. Orange and deep 
yellow vegetables are rich sources of antioxidant carotenoids. The β-carotene content of 
these foods is 5054 µg for 1 medium carrot, 11062 µg for 1 medium sweet potato, 6050 
µg for 1 cup of winter squash and 3800 µg for 1 cup of pumpkin. Although there are no 
dietary reference intakes for carotenoids, 5000 µg of β-carotene would provide 417 µg of 
retinol activity equivalents, which alone would meet half the RDA for vitamin A (900 µg 
for males and 700 µg for females of retinol activity equivalents). Thus, even one deep 
yellow orange vegetable per day would provide significant amounts of antioxidant 
carotenoids such as β-carotene.  The most significantly correlated vegetable subgroup 
was the “other vegetable” subgroup. One of the foods in that subgroup are peppers, which 
are not only high in antioxidants such as carotenoids and ascorbic acid but also contain 
capsaicinoids and capsinoids [209]. Preliminary in vitro and animal studies have 
demonstrated the anti-inflammatory capacity of capsaicinoids and capsinoids [210, 
211].  However, caution should be taken in trying to attribute the mechanism of a diverse 
and complex food group to single nutrients or compounds. For example, this lesson was 
learned in the ATBC (α-tocopherol, β-carotene) cancer prevention trial in smokers [212]. 
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Epidemiological evidence had suggested a decreased risk of lung cancer with higher 
dietary intakes of β-carotene; however, supplementation with purified β-carotene actually 
produced the opposite effect and increased lung cancer risk. The benefits seen with 
vegetable intake and chronic disease, including periodontal disease, are therefore likely 
due to a vast number of bioactive compounds. There are over 5000 phytochemicals 
present in plant-based foods with many more still undiscovered [213]. Furthermore, it is 
likely that the synergistic effects of many bioactives are responsible for the health 
benefits seen with higher fruit and vegetable intake [214]. For example, the total 
antioxidant capacity of 1 gram of apples is the equivalent to 1500 mg of vitamin C. That 
is, vitamin C only accounts for 0.04% of the antioxidant capacity in one gram of apples 
[215]. The bottom line message is that future nutritional research into chronic disease 
prevention and management will likely need to focus on whole foods rather than purified 
nutrients, and periodontal disease is no exception. Data from our study corroborates this 
idea as improved periodontal outcomes were seen with higher vegetable intake while no 
benefits were seen with use of dietary supplements. Therefore, vegetable intake should be 
further researched as a potentially positive modulator of periodontal healing following 
sanative therapy.  
 
Summary 
 The findings from this study broadly reflect the nutritional recommendations for 
healthy eating set by organizations such as Health Canada. It is likely not a coincidence 
that the dietary intake levels identified in this study are similar to the dietary 
recommended intakes and the dietary guidelines. Patients undergoing sanative therapy 
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can therefore be directed to follow current guidelines for essential fatty acid intake and 
for fruit and vegetable intake, which will have multiple benefits. Firstly, through possible 
optimization of sanative therapy, patients may experience greater improvements in 
periodontal healing and decreased risk of tooth loss. Secondly, patients will experience 
benefits to overall health and decrease their risk for chronic diseases such as diabetes, 
cardiovascular disease and osteoporosis as the dietary guidelines have been designed to 
address multiple health outcomes. This speaks to the broadening scope of dental practice 
where clinicians can, in addition to improving oral health, improve the overall health and 
well being of their patients.       
 
5.2 Conclusions 
Higher intakes of vitamin C, vitamin D, EPA and DHA, either through diet and/or 
supplement use was not associated with improved periodontal outcomes after sanative 
therapy. Similarly, higher serum 25-hydroxyvitamin D levels were also not associated 
with improved periodontal outcomes after sanative therapy. However, higher intakes of 
LA, ALA and vegetables (particular carotenoid rich orange yellow vegetables, legumes, 
and other vegetables such as peppers) as well as a lower total omega-6 to omega-3 ratio 
were associated with greater reductions in probing depth following sanative therapy. 
Dietary strategies that increase vegetable intake and ALA intake while maintaining LA 
intake may help improve periodontal healing following sanative therapy, ultimately 
leading to greater tooth retention and greater overall health.   
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 This was one of the first studies to investigate the relationship between diet and 
periodontal outcomes following sanative therapy and thus provides a strong basis for 
planning future research in this area.  
  
6.1 Future Observational Studies  
 One possible route might be to confirm and elaborate on the findings of this 
study. As this is the first study to report better periodontal healing with higher intakes of 
vegetables and ALA, an important step would be to be able to replicate these findings. 
The findings should also be replicated using different methods to quantify dietary intakes. 
In the current study, a food frequency questionnaire was used to quantify usual dietary 
intakes and therefore a future study might want to look more specifically at quantifying 
what was eaten during the two-month healing period. For that, a method such as a diet 
record could be useful or even new types of technology that are currently being 
developed to monitor food intake could be used. For example, the Remote Food 
Photography Method, where participants take photographs of food selection and plate 
waste, has been shown to be much more accurate than self-reported food intake [216]. 
Intakes of fruit, vegetables and specific fatty acids can also be assessed through 
biomarkers. Measuring a panel of biomarkers in plasma such as α- and β-carotene, 
vitamin C, lutein, zeaxanthin and β-cryptoxanthin may be useful in predicting fruit and 
vegetable intake [217] and there are many options available to assess fatty acid status 
[218]. In addition to quantifying dietary intakes, a future study could also increase the 
number of clinical outcomes measured to more fully characterize the effects of diet. For 
example it would be useful to measure clinical attachment loss in order to look at the 
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association between diet and periodontal regeneration as well as overall healing. It would 
also be interesting to know the long-term effects of diet, which could be accomplished by 
following patients to a later date. Long-term follow-up would also allow for the 
monitoring of alveolar bone loss or gain using dental radiographs. Dental measurements 
could also be refined by taking baseline PD and CAL measurements at the start of the 
study (currently they are measured at a consultation). This would allow for the same 
hygienist who takes the re-exam measurements to take the baseline measurements thus 
reducing differences due to examiners. It would also remove any possible inaccuracies 
due to changes in clinical outcomes between the consultation and the treatment. Finally, 
possible mechanisms could be elucidated by measuring antioxidant capacity [219] and 
inflammation (e.g. C-reactive protein) in serum samples.  
 
6.2 Future Intervention Studies 
 In the literature, one of the major knowledge gaps identified was the lack of 
intervention studies in patients with periodontal disease. Although our study did not 
directly address this gap, this study establishes the framework for future intervention 
studies looking at optimization of periodontal healing through nutrition. Findings from 
this study will enhance the efficacy at which new dietary strategies are uncovered in 
clinical trials. For example, a clinical trial should focus on increasing consumption of 
whole foods rather than supplement use as dietary supplements were not found to be 
beneficial in this study. A variety of fruits and vegetables should be consumed although 
particular attention might want to be given to specific types of vegetables identified in 
this study such as ones rich in carotenoids. ALA intake could also be increased with 
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foods such as flaxseed, canola oil, flaxseed oil, almonds and soybeans. A simple study 
might include providing dietary guidelines to a treatment group while also providing a 
way of tracking diet to ensure modification occurs. A more costly but likely more 
effective study would be to provide a treatment group with a defined amount of fruit and 
vegetables and/or ALA rich foods. Intervention studies using fruits and vegetables have 
been successfully completed where different amounts of fruits and vegetables were 
provided to participants [207]. Similarly dietary modification to increase ALA intake can 
be accomplished by providing foods with flaxseed such as bars, muffins, bagels, tea 
biscuits or pasta [220]. Although studies with dietary supplements are attractive due to 
practicality, the results from this study suggest a whole food approach would be more 
effective. It might however be of interest to compare a whole food approach to a dietary 
supplement (like the fruit and vegetable capsule used by Chapple et al. [205]) in a parallel 
study design. Any of the intervention studies could use nutritional biomarkers to assess 
compliance with treatments and the same details in the periodontal examination that were 
described in section 6.1 could be taken into consideration. Results from such a trial would 
be essentially in determining if the dietary components identified in the current study do 
in fact modulate periodontal outcomes. This would be a large step forward in creating 
dietary strategies to optimize periodontal healing following sanative therapy, which 
would ultimately lead to greater tooth retention and greater overall health.    
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